Methods for treating enteric injury

Bifidobacterium infantis administration addresses the lack of effective treatments for FPIAP and FPIES by restoring the infant gut microbiome, effectively resolving symptoms and reducing the risk of future allergies and asthma.

WO2024254188A2PCT designated stage expired Publication Date: 2024-12-12INFINANT HEALTH INC
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
PCT/US2024/032607
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-05
Filing Date
2024-06-05
Publication Date
2024-12-12

AI Technical Summary

Technical Problem

Current management of Food Protein-Induced Allergic Proctocolitis (FPIAP) and Food Protein-Induced Enterocolitis Syndrome (FPIES) in infants lacks effective non-invasive biomarkers and therapeutic options beyond dietary changes, with probiotics showing no impact on inflammation or symptom resolution.

Method used

Administration of Bifidobacterium infantis as a live biotherapeutic agent to infants, either alone or in combination with other elements, to restore the gut microbiome and reduce inflammation, thereby resolving symptoms of hematochezia and associated pathologies.

Benefits of technology

Bifidobacterium infantis effectively resolves FPIAP and FPIES symptoms in infants, reducing the risk of future health issues like IgE-based food allergies and asthma, by restoring the gut microbiome and minimizing long-term pathology impact.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024032607_12122024_PF_FP_ABST
    Figure US2024032607_12122024_PF_FP_ABST
Patent Text Reader

Abstract

The technology described herein is directed to medicament compositions and methods of monitoring, treating, and preventing a non-IgE food allergy such as Food Protein Induced Allergenic Proctocolitis (FPIAP) or Food Protein Induced Enterocolitis Syndrome (FPIES). The medicament can comprise bacteria such as Bifidobacterium strains, or bioproducts thereof, in order to increase expression of certain HMO utilization genes (HUGs) considered protective against food allergy.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No: 096910-000100WOPT METHODS FOR TREATING ENTERIC INJURY CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No.63 / 471,087 filed June 5, 2023, the contents of which are incorporated herein by reference in their entirety. TECHNICAL FIELD

[0002] The inventions described herein relate generally to the treatment of intestinal injury, digestive and immunological issues in newborn infants. BACKGROUND

[0003] Infant GI tracts are immature at birth and infants are at risk of hematochezia or bloody stool. There can be different causes depending on whether the infant is preterm or term.

[0004] Food Protein-Induced Allergic Proctocolitis (FPIAP), Food protein enteropathy (FPE) and Food Protein-induced enterocolitis Syndrome (FPIES) represent a spectrum of delayed inflammatory non-IgE mediated gut food allergy in infants. Symptoms usually start at one to four weeks of age and range from having gross blood in the stools, which is sometimes seen with mucous in the stool, to blood stained loose stools or diarrhea. Infants with FPIAP are usually otherwise healthy and growing well. FPIAP occurs in breastfed infants but can also occur if cow’s milk or soy based nutrition is commenced. In contrast, FPIES is more severe and can result in severe vomiting, diarrhea and dehydration, and failure to thrive (see e.g., Labrosse et al, Nutrients, 2020 Jul 14;12(7):2086, the content of which is incorporated herein by reference in its entirety).

[0005] Diagnosis is generally based on excluding other causes of blood in the stool or blood stained diarrhea. If FPIAP is considered likely, symptoms should resolve once the offending food / s are eliminated from the mother’s and / or infant’s diet. After symptoms have resolved, the offending food / s can be re-introduced to confirm the diagnosis. Children typically outgrow FPIAP by 3-5 years of age.

[0006] Conventional management of FPIAP in the breast-fed infant involves removal of cow’s milk and all other dairy products from the mother’s diet. Many cases will resolve with elimination of cow’s milk. If symptoms do not resolve, further changes to the breastfeeding mother’s diet can be made. Once symptoms have resolved, the eliminated foods can be re-introduced into the breastfeeding mother’s diet to confirm the diagnosis and identify the causative food. FPIES can be mistakenly diagnosed early on as a potential severe blood infection or repeated infections of a gastrointestinal virus. There is no blood or skin testing available for diagnosis of FPIES. The primary treatment for FPIES is strict avoidance of the triggering food.

[0007] Restriction of specific food protein from the breastfeeding mother’s diet is done under supervision by a dietitian, to ensure caloric, vitamin and mineral adequacy and to prevent excess weight 1  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT loss in the mother. If FPIAP symptoms in the infant cannot be resolved by changes in the maternal diet, a change in the infant’s diet to an extensively hydrolyzed infant formula can be done.

[0008] FPIAP management for a formula-fed infant can require restricting the infant’s diet under medical supervision in order to ensure the infant receives optimal nutrition. If the dietary restriction shows no improvement in 7-14 days, the medical professional can prescribe an extensively-hydrolyzed formula (EHF) or an amino-acid-based-formula (AAF).

[0009] Resolution of FPIAP usually occurs in 50% of infants by the age of six months, and 95% of infants by the age of nine months. However, the primary cause of the FPIAP is still unknown, and early life allergenic or inflammatory events in the gastrointestinal tract can trigger the onset of persistent digestive symptoms later in life, particularly irritable bowel syndrome (IBS). In a recent real world analysis, it was determined that, adjusting for eczema, children with FPIAP had twice the odds of developing IgE-based food allergies.

[0010] There are currently no non-invasive biomarkers identified to support the diagnosis of FPIAP. Risk factors for the development of FPIAP are not known. A recent systematic review of 10 randomized controlled trials (RCTs) using probiotics for the resolution of cow’s milk allergy concluded that probiotic supplementation had no impact on resolution of hematochezia (blood in the stools).

[0011] FPIAP is typically identified clinically by the presence of bloody or mucoid stools during the first few months of life in an outwardly healthy infant. It can be linked to a number of pathologies later in life, and in the US, it is reported to have a 1%-20% incidence. At this time there are no therapeutic options for the resolution of FPIAP other than dietary changes of the mother and / or the infant. See e.g., Nardo et al., Pediatrics 142(Supp 4): S245–S246 (2018); Martin et al., Pediatrics 146(3): e20200202 (2020); Martin et al., J Allergy Clin Immunol Pract 8(5): 1692-1699 (2020); Qamer et al., European Journal of Pediatrics 178: 1139–1149 (2019); Caubet et al. Allergy Immunol, 28, 6-17 (2017); Venter et al. (2017). Clin Transl Allergy, 7, 26; the contents of each of which are incorporated herein by reference in their entireties. FPIES can also include profuse vomiting in the hours following feeding.

[0012] GERD (gastroesophageal reflux disease) can also cause bloody stool in infants. Elimination diets and / or GERD medication are typically used in clinical management of symptoms. SUMMARY

[0013] Described herein are Bifidobacterium-based medicaments and uses of such medicaments that allow for the prevention and / or resolution of hematochezia and / or FPIAP / FPIES that minimize consequential impact on the development of associated or related pathologies in the future.

[0014] Described herein is the discovery that certain non-IgE-based allergenic responses early in infancy are associated with a disruption of the infant gut microbiome in both breast-fed and formula- fed infants. These conditions include, but are not limited to, hematochezia in preterm infants, Food Protein Induced Allergenic Proctocolitis (FPIAP) and Food Protein Induced Enterocolitis Syndrome 2  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT (FPIES) and can be manifest in the first few weeks to months of life. As described herein, chronic enteric inflammation was identified in patients with FPIAP, as reflected in elevated levels of certain proinflammatory cytokines and other inflammatory markers in these patients. This gut inflammation also results in elevated inflammatory biomarkers in systemic circulation. FPIAP is also associated with erosion of the gut mucous layer and the intestinal epithelium producing the appearance of blood in the stools. FPIES is also associated with severe vomiting, diarrhea, and dehydration typically two hours after eating certain foodstuffs.

[0015] There can be other reasons for hematochezia including prematurity and GERD.

[0016] In contrast to the state of the art which indicates that probiotics are ineffective at reducing the inflammation or resolving the symptoms of FPIAP, described herein is the discovery that when Bifidobacterium infantis is provided to the infant as a medicament (e.g., as a live biotherapeutic (LBT) in an appropriate daily dose), the symptoms of FPIAP, including hematochezia (blood detected in the stool) are resolved in 1-9 months.

[0017] Resolution of FPIAP early in life using the compositions and methods described herein also significantly reduces the risk of future health issues including, but not limited to FPIES, atopic dermatitis, IgE-based food allergies, asthma, Spontaneous Intestinal Perforation (SIP), and Necrotizing enterocolitis.

[0018] Described herein are Bifidobacterium-based medicaments and uses of such medicaments that allows for the prevention and / or resolution of hematochezia, and / or FPIAP / FPIES that minimizes its consequential impact on the development of associated or related pathologies in the future.

[0019] In some embodiments, a medicament comprising one or more Bifidobacterium species can be used in an infant patient exhibiting symptoms of bloody stool.

[0020] In some embodiments, the Bifidobacterium species is selected from the group consisting of: Bifidobacterium breve, Bifidobacterium longum subsp longum, Bifidobacterium longum subsp infantis, Bifidobacterium longum subsp suis, Bifidobacterium pseudolongum, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Bifidobacterium catenulatum, Bifidobacterium bifidum, and Bifidobacterium dentium.

[0021] In other embodiments, a medicament comprises B. longum subspecies infantis. In some cases, the Bifidobacterium can be selected because of a functional H5 gene cluster that transports and metabolizes certain types of HMO. The type of HMO has a lacto-N-biose core. These types of HMO are present in human milk.

[0022] In some cases, the functional H5 gene cluster comprises genes with greater than 90% sequence identity to the nucleic acid sequences of Blon_2171, Blon_2172, Blon_2173, Blon_2174, Blon_2175, Blon_2176, and / or Blon_2177. In other cases, the functional H5 gene cluster is capable of expressing Blon_2171, Blon_2172, Blon_2173, Blon_2174, Blon_2175, Blon_2176, and Blon_2177. 3  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT

[0023] In yet other embodiments, the function of the Bifidobacterium is assessed by expression and activity of Blon_2176 in a reconstituted dried Bifidobacterium species or strain to transport and metabolize HMO structures with lacto-N-biose cores present in human milk.

[0024] In some cases, the Bifidobacterium species expresses genes with at least 75% sequence identity to at least 9 of the genes selected from the group consisting of: Blon 2334-2336, Blon 0243- 0248, and Blon 0423-0428.

[0025] In some embodiments, the Bifidobacterium species is B. infantis strain EVC001 (ATCC Accession No. PTA-125180) or ATCC strain 15697. In some cases, the Bifidobacterium is activated.

[0026] In some embodiments, the infant patient receives 101to 1013cfu of the Bifidobacterium per day; or at least 10 million – 100 million CFU of the Bifidobacterium per day; or at least 100 million to at least 1 Billion CFU of the Bifidobacterium per day or at least 1 billion to at least 8 billion CFU of the Bifidobacterium per day. In some embodiment, the Bifidobacterium is provided in a unit dose of 101to 1013cfu per dose. The unit dose can be given 1-12 times per day to reach the total daily intake. In some embodiments, the Bifidobacterium is in combination with a cryoprotectant. The cryoprotectant is selected from the group consisting of: sucrose, trehalose, maltodextrin, inulin, pea protein, milk fat globule membrane, glycomacropeptide (GMP), LNT, and LNnT, and combinations thereof.

[0027] The cryoprotectant and Bifidobacterium mixture can be frozen as a liquid product or dried (freeze-dried or spray-dried). The Bifidobacterium is in combination with an excipient selected from the group consisting of: lactose, MCT oil, MFGM, maltodextrin, LNT, LNnT, 2’FL, 3FL, infant formula, an exempt infant formula, human milk fortifier, and human milk product, and combinations thereof.

[0028] In some embodiments medicaments further comprise a second, third or fourth component selected from an HMO, a vitamin, and / or a source of DHA or other bacterial species.

[0029] In some embodiments a) the HMO can be selected from one of more of the group consisting of: lacto-N-biose (LNB), N-acetyl lactosamine, lacto-N-triose, lacto-N-tetraose (LNT), lacto-N- neotetraose (LNnT), fucosyllactose (FL), lacto-N-fucopentaose (LNFP), lactodifucotetraose, (LDFT) sialyllactose (SL), disialyllacto-N-tetraose (DSLNT), 2'- fucosyllactose (2FL), 3’-sialyllactosamine (3SLN), 3'-fucosyllactose (3FL), 3'-sialyl- 3-fucosyllactose(3S3FL), 3'-sialyllactose (3SL), 6'-sialyllactosamine (6SLN), 6'- sialyllactose (6SL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFPI), lacto- N-fucopentaose II (LNFPII), lacto-N-fucopentaose III (LNFPIII), lacto-N- fucopentaose V (LNFPV), and sialyllacto-N-tetraose (SLNT), and their derivatives, and combinations thereof; b) the HMO can be LNT at 0.5 -10g / d; 4  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT c) the vitamin is selected from the group consisting of: Vitamin A (retinol, carotenoids), Vitamin B (thiamine, riboflavin, niacin, niacinamide, pantothenic acid, pyridoxine, pyradoxamin, pyridoxal, biotin, folic acid, folate, folic acid, cyanocobalamin, hydroxocobalamin, methylcarbylamine), Vitamin C (ascorbic acid), Vitamin D (cholecalciferol, ergocalciferol), Vitamin E (tocopherols, tocotrienols), and Vitamin K (phylloquinone, menaquinone); d) the Vitamin D can be at 5-25 ug / d; e) the DHA source can be selected from the group consisting of: fish oil, algal oil, and oil from recombinant plants or microorganisms; f) the DHA can be a triglyceride delivering 1-50 mg DHA / d; and / or g) the other bacterial species can be selected from Akkermansia and Lactobacillus, optionally wherein the Akkermansia species is selected from the group consisting of: Akkermansia muciniphila and Akkermansia glycaniphila; optionally wherein the Lactobacillus species is selected from the group consisting of: Lactobacillus crispatus, Lactobacillus johnsonii, Lacticaseibacillus rhamnosus, Limosilactobacillus reuteri, and Lacticaseibacillus paracasei.

[0030] In some embodiments, the medicament can be formulated as a powder, a gel, butter or paste, a liquid suspension, an oil, a foam. It can be formulated to be delivered orally and / or as a suppository.

[0031] In some embodiments, the medicament can comprise a food, a food for special dietary use (FSDU), a medical food, a dietary supplement, or a live bacterial therapeutic (LBT).

[0032] The medicament can be manufactured and packaged at a pharmaceutical grade for use as a live bacterial therapeutic.

[0033] In some embodiments an FSDU, medical food and / or dietary supplement can be used in combination with a preterm infant formula, term infant formula, soy-based formula, follow-on formula, bovine based human milk fortifier, human based human milk fortifier, expressed human milk, expressed pasteurized donor milk, enriched human whey permeate (dried or liquid), or purified human milk oligosaccharides from natural or synthetic sources.

[0034] The medicament can be added to the FSDU, medical food and / or dietary supplement at time of manufacture or at the time of consumption.

[0035] The unit size of the FSDU, medical food and / or dietary supplement can be a single serving or dose.

[0036] In some embodiments, the medicament is formulated for consumption by the infant patient.

[0037] In some embodiments, the medicament prevents, treats, reduces, or resolves hematochezia and / or anemia in the infant patient. In other embodiments, the medicament treats, 5  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT reduces, or resolves symptoms of FPIAP and FPIES in the infant patient. In yet other embodiments, the medicament prevents FPIAP or FPIES in the infant patient.

[0038] In some embodiments, the infant patient can be a term infant. The term infant’s age is 0-3 months, 0-6 months, 6-12 months, 21-24 months, or 0-24 months. The infant patient can be a preterm infant. The preterm infant can be extremely low birth weight (ELBW), very low birth weight (VLBW), low birth weight (LBW) and / or less than 33 weeks gestational age at birth or less than 31 weeks.

[0039] In any embodiment, the infant patient can be selected from an infant with risk factors for bloody stool selected from the group consisting of: prematurity, family history of bloody stool or food allergy, past history of atopic dermatitis, gut dysbiosis, C- section, antibiotic use, and cow’s milk protein sensitivity.

[0040] In other embodiments, the patient or patient population can be selected based on onset of symptoms selected from the group consisting of: bloody stools, IgE antibodies, autoantibodies, excessive crying, low anthropometric scores, poor cognitive scores, high level of enteric or systemic inflammation (e.g., > 200ug / mg fecal calprotectin), feeding difficulty, wheezing, vomiting, and reflux (GERD).

[0041] In any embodiments, any medicaments described herein, can be used for treating, preventing or reducing the severity of FPIAP, wherein the method comprising administering a medicament to an infant subject in need thereof.

[0042] In some embodiments, the medicament can be administered in a background of or in combination with cow’s milk protein. Cow’s milk protein can be from addition of bovine based infant formula, transfer through breast milk (e.g., increased dairy consumption by a breast-feeding mother), yogurt, or cheese to the infant diet.

[0043] In some cases, A method of administering a medicament described herein, can be used to treat hematochezia in an infant subject in need thereof. The hematochezia can be associated with FPIAP or FPIES. The medicament can be provided within 1 hour, 2 hours, or up to 5 days after the day of diagnosis; and / or on a daily basis for at least 1-100 days; and / or until hematochezia or bloody stool is resolved; and / or one or more times / day but not exceeding the total daily intake.

[0044] In some embodiments, the treatment is initiated within the first year of life.

[0045] In other embodiments, the treatment is provided to one or both of a mother-infant pair in conjunction with breast-feeding. In some embodiments, breastfeeding duration is increased. In some embodiments, the mother being treated can be in the 3rdor 4thtrimester, or wherein the mother can be breast-feeding.

[0046] In some embodiments, a method of treating FPIAP or FPIES can comprise a) identifying an infant patient with FPIAP by any one of the following symptoms: i) elevated stool inflammatory markers; ii) elevated eotaxin levels; iii) bloody stool; iv) stool B. infantis comprising less than 5% of the infant gut microbiome; v) stool Enterobacteriaceae exceeding 20% of the infant gut microbiome; 6  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT vi) excess stool mucus; and / or vii) wheezing, vomiting, and / or reflux (gastrointestinal reflux or GERD); B) providing the patient with a medicament described herein according to the daily dose; and in some embodiments C) monitoring the symptoms of the patient until any or all of the symptoms are resolved.

[0047] In some embodiments, a method of treating hematochezia can comprise: identifying an infant patient with hematochezia using a stool occult test; providing the patient with a medicament described herein according to the daily total intake; and monitoring the patient until the hematochezia is resolved.

[0048] In some embodiments, A medicament described herein is used as a method of reducing the risk of IgE-based food allergies and / or asthma by treating patients with FPIAP or FPIES with said medicament. In some embodiments, the risk of IgE mediated egg, milk or peanut allergy is reduced.

[0049] In some embodiments, treatment efficacy can be measured by one or more of: decreased gut pH, a change in metagenomic sequencing, reduction or enrichment of at least one metabolite, and / or change in inflammatory profile. In some embodiments, the metabolite can be selected from the group consisting of: adenine, N-acetylgluco-saminyl-asparagine, sphingomyelin, PAHSA, gamma- glutamylmethionine, glutamate gamma-methyl ester, lactate, sedoheptulose, indolelactate, N- acetylneuraminate (Neu5Ac), gulonate, serotonin, OH-PLA, indole, phenyllactate (PLA), 4-hydroxy- phenyllactate (4-OH-PLA), and nicotinamide riboside. In some embodiments, the change in metagenomic sequencing can comprise: an enrichment of HMO metabolizing genes and / or aromatic lactic acid pathways, and / or a reduction of antibiotic resistance genes and / or formate biosynthesis pathways. In other embodiments, the change in metagenomic sequencing can comprise B. infantis comprising greater than 30% of the total gut microbiome and Enterobacteriaceae comprising less than 20% of the total gut microbiome.

[0050] In other embodiments, the inflammatory profile can comprise levels of one or more inflammatory cytokines selected from the group consisting of: IL-1α, MIP1a, GM-CSF, TARC, MIP- 1B, IL-16, IL-2, MCP-1, MCP-4, VEGF, IFN-β, IL-13, MIP-3a, IL-17A, IL-31, IL-21, IL-33, and eotaxin.

[0051] In some embodiments, fecal IL-1α, IFN-β, and Galectin-1 can be increased, and fecal GM-CSF, TARC, MIP-1B, MCP-1, MCP-4, VEGF, IL-13, MIP-3a, IL-17A, IL-31, IL-21, IL-33, and eotaxin can be decreased in comparison to pretreatment samples and / or control subject samples.

[0052] In any embodiment, described herein is a method of treating FPIAP or FPIES in an infant in need thereof, the method comprises administering a composition comprising a therapeutically effective amount of a Bifidobacterium to the infant, whereby FPIAP or FPIES can be treated. In some embodiments, the method further comprises the step of monitoring the patient until any or all of the symptoms of FPIAP or FPIES are resolved. In some embodiments, the method further comprises a step, before the administering step, of receiving diagnostic results indicating that the subject has 7  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT FPIAP or FPIES. In some embodiments, the method further comprises a step, before the administering step, of performing a diagnostic test for FPIAP or FPIES.

[0053] In some embodiments, diagnosis is based on one or more markers, which can be selected from the group consisting of: elevated stool inflammatory markers, stool B. infantis comprising less than 5% of the infant gut microbiome, stool Enterobacteriaceae exceeding 20% of the infant gut microbiome, and excess stool mucus. In some embodiments, one or more stool inflammatory markers are selected from the group consisting of: IL-1α, MIP1a, GM-CSF, TARC, MIP-1B, IL-16, IL-2, MCP-1, MCP-4, VEGF, IFN-β, IL-13, MIP-3a, IL-17A, IL-31, IL-21, IL-33, and eotaxin.

[0054] In any embodiment, the medicament is a method which can treat hematochezia. The method can comprise administering to a subject diagnosed with hematochezia, a composition comprising a Bifidobacterium in an amount effective to treat hematochezia, whereby the hematochezia can be treated.

[0055] In some embodiments, the method further can comprise identifying a patient at risk for hematochezia, using risk factors selected from the group consisting of: prematurity, low gestational age, low birth weight, increased time on Total Parenteral Nutrition (TPN), increased time to full feeds, increased nil per os (NPO), elevated stool inflammatory markers, stool B. infantis comprising 5% of the total gut microbiome, and Enterobacteriaceae comprising greater than 45%.

[0056] In some embodiments, the hematochezia can be determined to be effectively treated when there is a decrease in time to full feeds, decrease in nil per os (NPO), and decrease in time on TPN.

[0057] In some embodiments, the hematochezia can be determined to be effectively treated when B. infantis can comprise over 30% of the total gut microbiome and Enterobacteriaceae can comprise less than 30%. In some embodiments, the method further comprises a step, before the administering step, of receiving diagnostic results indicating that the subject has hematochezia.

[0058] In some embodiments, the method can reduce the incidence of spontaneous intestinal perforation, late onset sepsis, anemia, and / or necrotizing colitis. In some embodiments, the method further comprises a step, before the administering of medicament step, of performing a diagnostic test for hematochezia.

[0059] In any embodiments, the medicament can serve as a method for reducing the risk of IgE- based food allergy or asthma in an infant with FPIAP or FPIES. The treatment can involve administering a composition comprising a therapeutically effective amount of a Bifidobacterium to the infant, whereby the infant’s risk of IgE-based food allergy can be reduced relative to an infant with FPIAP or FPIES not administered the composition. In some embodiments, the Bifidobacterium is in a medicament with a composition described herein.

[0060] In some embodiments, a composition can comprise a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis EVC001 for use in the treatment of FPIAP or FPIES, which is effective when reconstituted in vivo. 8  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT

[0061] In some embodiments, the B. infantis medicament can be reconstituted at the time of consumption or in vivo.

[0062] In some embodiments, a medicament can comprise a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis for use in treating hematochezia, which is effective when reconstituted in vivo.

[0063] In some embodiments, the B. infantis can be reconstituted at time of consumption or in vivo.

[0064] In some embodiments, a medicament can comprise a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis EVC001 for use in reducing the risk of IgE-based food allergy or asthma in an infant with FPIAP or FPIES, which is effective when reconstituted in vivo.

[0065] In some embodiments, the dried B. infantis can be reconstituted at time of consumption or in vivo.

[0066] In one aspect, described herein is a method of treating, preventing, or reducing the severity of symptoms of bloody stool in an infant patient in need thereof, the method comprising administering an effective amount of a medicament comprising one or more Bifidobacterium species.

[0067] In one aspect, described herein is a method of treating, preventing, or reducing the severity of FPIAP, the method comprising administering an effective amount of a medicament comprising one or more Bifidobacterium species to an infant subject in need thereof.

[0068] In one aspect, described herein is a method of treating hematochezia in an infant subject, the method comprising administering an effective amount of a medicament comprising one or more Bifidobacterium species to an infant subject in need thereof.

[0069] In one aspect, described herein is a method of treating FPIAP or FPIES comprising: (a) identifying an infant patient with FPIAP by any one of the following symptoms: (i) elevated stool inflammatory markers; (ii) elevated eotaxin levels; (iii) bloody stool; (iv) stool B. infantis comprising less than 5% of the infant gut microbiome; (v) stool Enterobacteriaceae exceeding 20% of the infant gut microbiome; (vi) excess stool mucus; and / or (vii) feeding difficulty, wheezing, vomiting and / or reflux (e.g., Gastroesophageal Reflux Disease, GERD); (b) providing the patient with an effective amount of a medicament comprising one or more Bifidobacterium species according to a daily dose; and (c) monitoring the symptoms of the patient until any or all of the symptoms are resolved.

[0070] In one aspect, described herein is a method of treating hematochezia comprising: identifying an infant patient with hematochezia using a stool occult test; providing the patient with an effective amount of a medicament comprising one or more Bifidobacterium species according to a daily total intake; and monitoring the patient until the hematochezia is resolved.

[0071] In one aspect, described herein is a method of reducing the risk of IgE-based food allergies and / or asthma by treating patients with FPIAP or FPIES with an effective amount of a medicament comprising one or more Bifidobacterium species. 9  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT

[0072] In one aspect, described herein is a method of treating, preventing, or reducing the severity of FPIAP or FPIES in an infant in need thereof, the method comprising administering a composition comprising a therapeutically effective amount of a Bifidobacterium to the infant, whereby FPIAP or FPIES is treated, prevented, or severity reduced.

[0073] In one aspect, described herein is a method of treating, preventing, or reducing the severity of hematochezia, the method comprising administering to a subject diagnosed with hematochezia, a composition comprising a Bifidobacterium in an amount effective to treat, prevent, or reduce the severity of hematochezia, whereby the hematochezia is treated, prevented, or the severity reduced.

[0074] In one aspect, described herein is a method for reducing the risk of IgE-based food allergy or asthma in an infant with FPIAP or FPIES, the method comprising administering a composition comprising a therapeutically effective amount of a Bifidobacterium to the infant, whereby the infant’s risk of IgE-based food allergy is reduced relative to an infant with FPIAP or FPIES not administered the composition.

[0075] In one aspect, described herein is a method of treating, preventing, or reducing the severity of FPIAP or FPIES, the method comprising administering a composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis EVC001, which is effective when reconstituted in vivo.

[0076] In one aspect, described herein is a method of treating, preventing, or reducing the severity of hematochezia, the method comprising administering a composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis, which is effective when reconstituted in vivo.

[0077] In one aspect, described herein is a method of reducing the risk of IgE-based food allergy or asthma in an infant with FPIAP or FPIES, the method comprising administering a composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis, which is effective when reconstituted in vivo.

[0078] In one aspect, described herein is a composition comprising one or more Bifidobacterium species for use in an infant patient exhibiting symptoms of bloody stool.

[0079] In one aspect, described herein is a composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis EVC001 for use in the treatment of FPIAP or FPIES, which is effective when reconstituted in vivo.

[0080] In one aspect, described herein is a composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis for use in treating hematochezia, which is effective when reconstituted in vivo.

[0081] In one aspect, described herein is a composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis for use in reducing the risk of IgE-based 10  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT food allergy or asthma in an infant with FPIAP or FPIES, which is effective when reconstituted in vivo.

[0082] Further embodiments of the use-limited compositions parallel the embodiments set out in regard to the methods of treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0083] Figure 1 shows a sample collected at 6 months (or next closest samples not exceeding 6 months) postnatal in which subjects were separated into groups based on titer of IgE antibodies to milk (Milk Allergy True) or not (Milk Allergy False), and KEGG CPM values were compared between groups using Wilcoxon-Mann-Whitney test with FDR-correction. Within the ‘HMO Carbohydrate Metabolism’ and ‘Carbohydrate Transport’ KEGG pathway CPM values were significantly higher in Milk Allergy False compared to Milk Allergy True (P < 0.01; P < 0.0001, respectively). FDR-corrected P values were considered statistically significant if * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001.

[0084] Figure 2 shows the fecal sample correlation of infants fed B. infantis EVC001 of KEGG function and metabolites from the IMPRINT trial. CPM values of functional KEGG orthologs (KOs) associated with the utilization of HMOs were correlated with scaled metabolite profiles in an all- against-all Spearman Correlation matrix for 21 subjects from the IMPRINT trial fed B. infantis EVC001. P-values were FDR-corrected, and correlations with adjusted p-values < 0.05 were considered statistically significant. Significant correlations were plotted on a heatmap with the shade representing the Spearman’s Rho value. The heatmaps were separated based on the general pathway that the KOs represent.

[0085] Figure 3A–3F shows fecal cytokine concentration of newborn infants and individual HMO-utilization gene (HUG) abundance (counts per million (CPM)). A total of 40 fecal samples from exclusively breastfed infants (n = 20 controls; n = 20 fed daily 1.8 x 1010CFU B. infantis EVC001 from day 7-28 postnatal) were evaluated with metagenomic sequencing at day 21 postnatal and fecal enteric inflammatory profile at day 40 or day 60 postnatal. Fig.3A-3C show fecal calprotectin, IL-5, and IL-1b concentrations of day 40 postnatal, which were evaluated based on HUGs CPM at day 21. Calprotectin concentration did not substantially change when HUGS CPM increased; however, fecal IL-5 and IL-1B levels were substantially lower when HUGS CPM values were > 10 and > 1, respectively. Fig.3D-3F shows that fecal IL-4, IL-13, IL-17A concentration was substantially lower when newborn children had functional capacity to break down HMOs with a HUG CPM value > 10, 10, and 100, respectively. These data highlight how the functional capacity of the gut microbiome impacts host enteric inflammatory profile. The left-right order of the bars in Fig.3A- 3F correspond to the top-down order of the legend.

[0086] Figure 4A-4F show IECs treated with EVC001 fecal water (FW) significantly increased enterocyte proliferation. In Fig.4 cell cultures were grown in 5% pooled EVC001 FW, control FW, 11  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT or medium supplemented with 5% PBS. Fig.4A shows a HIEC-6 cell line; Fig.4B-4D shows proliferating cells; and Fig.4E-4F show differentiated small intestine and colon primary cells grown in different mediums. Control FW Data sets are representative of at least three different experiments completed in triplicate and Mann-Whitney test was used to determine significance with corresponding P values considered statistically significant if *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

[0087] Figure 5A-5C shows mitochondrial respiration and capacity of IECs were increased when treated with EVC001 FW compared to Control FW. Primary IECs exposed to EVC001 FW and Control FW were evaluated using Seahorse Mitochondrial Functional Assays and showed significantly increased (Fig 5A) basal, (Fig 5B) ATP linked and (Fig 5C) Max Respiration in cells treated with EVC001 FW compared to Control FW (P = 0.0023, P = 0.018, and P = 0.015, respectively). Data sets are representative of at least three different experiments completed in triplicate and Mann-Whitney test was used to determine significance with corresponding P values considered statistically significant if *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

[0088] Figure 6A-6C shows cytotoxic and protective effects of FW on enterocytes. Adult (Fig. 6A) and premature enterocyte (Fig.6B) cell lines were grown in medium supplemented with 5% pooled FWs from Control or EVC001 infants with LDH activity determined by fluorescent assay 24 post-exposure. LDH activity was significantly lower in Caco-2 cells grown with EVC001 FW compared to those grown with Control FW (P = 0.05) and HIEC-6 grown in Control and EVC001 FW produced significantly lower levels of LDH compared to medium alone (P = 0.01, 0.003, respectively). To evaluate whether FWs were protective against formate-induced growth failure, primary enterocytes were grown in Control FW, EVC001 FW, or media + PBS and challenged with 50mM formate grown for 48 hours (Fig.6C). WST8 Cell viability was significantly decreased in primary cells exposed to formate compared to controls (P = 0.0026). Control FW treated primary cells had significantly increased OD compared to medium alone (P = 0.015) and EVC001 FW treated primary cells showed significantly increased viability compared to medium alone and Control FW (P = 0.0022, P = 0.0043, respectively) after exposure to formate. Data sets are representative of at least three different experiments completed in triplicate and Mann-Whitney test was used to determine significance with corresponding P values considered statistically significant if *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

[0089] Figure 7A-7B shows cell growth accelerated by lactate and acetate exposure. Caco-2 cells were exposed to the predominant organic acids (acetate, lactate, butyrate, and formate) added at physiological concentrations quantified in fecal samples from infants fed EVC001 versus those that were not to complete growth media. Transepithelial electrical resistance (TEER) was evaluated as a measure of cell growth overtime. No cells were seeded in Medium with PBS wells as a negative control. Daily TEER measurements of Caco-2 cells exposed to physiological levels of tested organic 12  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT acids from Control infants showed no significant increase compared to unseeded negative control (Fig.7A). Acetate, lactate, and butyrate at physiological levels found in EVC001-fed infant fecal samples showed significantly increased TEER at d4 and d8 compared to unseeded medium alone (Fig.7B; acetate: P = 0.007, P = 0.005; lactate: P = 0.018, P = 0.002; butyrate: P = 0.006, P = 0.003). Formate exposure did not increase TEER measurement. Data sets are representative of at least three different experiments completed in triplicate and Mann- Whitney test was used to determine significance with corresponding P values considered statistically significant if *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. DETAILED DESCRIPTION

[0090] Described herein are compositions and methods for monitoring, treating, and preventing hematochezia in infant patients.

[0091] Described herein is the prevention or treatment of Food Protein Induced Allergic Proctocolitis (FPIAP) and Food Protein Induced Enterocolitis Syndrome (FPIES) using Bifidobacterium or a bacterial fermentation supernatant or derivative of the spent media produced by Bifidobacterium for use a medicament.

[0092] In some embodiments, the Bifidobacterium is administered as a live biotherapeutic agent alone, or in combination with other elements. Other elements can be added contemporaneously or sequentially to provide a treatment regime.

[0093] The compositions and methods described herein relate to the resolution of symptoms of FPIAP including hematochezia, disruptive stooling, alterations in the gut microbiome, and elevated gut inflammation. Described herein are medicaments and methods of resolving the symptoms of FPIAP in order to minimize consequences of the early life presentation of FPIAP on IgE-based food allergies and asthma later in life. FPIAP

[0094] Food protein-induced allergic proctocolitis (FPIAP) is characterized by inflammatory changes in the distal colon in response to one or more different food proteins because of immune- mediated reactions, in which the underlying mechanism is not known, though IgE is not implicated.

[0095] The symptoms typically begin in the first weeks to months of life, and infants with FPIAP usually present with blood and mucus mixed with stool, with or without diarrhea. Some affected infants are fussy and irritable, but most are generally healthy appearing.

[0096] FPIAP is a clinical entity, and the diagnosis is often made presumptively. There is no definitive diagnostic exam or test available. Various non-specific fecal markers such as, but not limited to calprotectin, myeloperoxidase, lactoferrin, and lipocalin-2, can be used, as well eotaxin from eosinophil infiltration, or as the disappearance of clinical symptoms when suppressing the culprit food, with clinical relapse when the food is reintroduced. In some embodiments, the level of a 13  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT FPIAP marker (e.g., calprotectin, myeloperoxidase, lactoferrin, and lipocalin-2) is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%.70%, 75%, 80%, 85% or at least 95% higher, or at least 1x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x higher than the level of the FPIAP marker in a normal control (e.g., an individual without symptoms of FPIAP or FPIES, such as a lack of bloody stool or hematochezia). Endoscopy generally shows focal or diffuse colitis, with edema and erosions.

[0097] Rectal bleeding is not a rare problem in otherwise healthy breast-fed infants. The differential diagnosis includes most commonly anal fissure, as well as intussusception, infectious colitis, necrotizing enterocolitis, and very early onset inflammatory bowel disease.

[0098] Cow's milk and sometimes soy is the most common trigger for FPIAP, though it is commonly characterized by multiple hypersensitivities to food. Common triggers for FPIES include cow milk, soy and grains, such as rice, barley, oats. The infant can be exposed to the cow's milk protein through breast milk or infant formula. The elimination diet is currently the essential method of treating allergic enteritis; see e.g., Mennini et al (2020) World Allergy Organization Journal 13:10, the content of which is incorporated herein by reference in its entirety. Infant Gut Microbiome

[0099] A gut or intestinal microbiome is the total community of microorganisms residing in the gastrointestinal tract of an individual. The gut microbiome can include bacteria, yeast, and viruses. The phrase “gut dysbiosis” as used herein can refer to the state of gut microbiome imbalance inside the body, resulting from an insufficient level of bacteria, referred to as “keystone” bacteria (e.g., Bifidobacteria, such as B. longum subsp. infantis) or an overabundance of harmful and potentially pathogenic bacteria in the gut. “Keystone” bacteria can perform functions that contribute to the balance of the microbiota, and thus deficiency or absence of such keystone species can lead to dysbiosis.

[0100] Gut dysbiosis can result at any age, and dysbiosis means a loss or absence of certain bacteria and bacterial functions that results in a loss of capability and performance in the gut microbiome that can lead to insufficient gut function leading to symptoms of reduced gut and / or overall health of the host. In infants, the absence of certain Bifidobacterium and the loss of the ability of the gut microflora to consume and / or metabolize HMO is a non-limiting example of infant gut dysbiosis.

[0101] Characteristics of the microbiome can be measured with Next Generation Sequencing (NGS) technology using a sufficient sequencing depth to identify the family level, to the species or subspecies level, or to be able to look at specific gene functions (metagenomics) to establish the relative abundance or certain taxa or genes within the total microbiome. Individual genus’ or species’ absolute abundance can be measured by quantitative Polymerase Chain Reaction (qPCR) by using primers specific to the organism in question and normalizing to micrograms of feces or micrograms of 14  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT DNA. A subject’s gut microbiome can be assessed for its overall abundance of Bifidobacteriaceae and / or Enterobacteriaceae.

[0102] Next generation genomic sequencing of fecal samples, such as shotgun methods, can provide detailed understanding of the genomic capacity or potential of a gut microbiome within a given patient or subject or population thereof. Metagenomic analysis links the abundance of genes (counts per millions; CPM) to the metabolic pathways that can be used to identify therapeutic metabolites (e.g., candidate small molecules) that are produced in certain microbiomes and can be tested for effectiveness in treating non-communicable diseases (NCDs) as small molecules or naturally-occurring recombinant organisms delivering the metabolites.

[0103] Microbiome function is the interaction between the genetic potential or capacity that results in an overall metabolic output of that microbiome. The microbiome function can be measured by gut pH, other biochemical markers, metagenomic sequencing, absence or presence of specific metabolites coded by Human Milk Utilization Genes (HUGs,) and / or decreased enteric and systemic inflammatory biomarkers. A biomarker is one or more analytical output(s) that can be used in the assessment of microbiome function and categorization of risk. An inflammatory marker can be interferon beta and / or Galectin-1.

[0104] Dysbiosis in a human infant is a microbiome that does not comprise B. longum subsp. infantis at levels of at least 108cfu / g fecal material during the first 12 months of life. Dysbiosis can be further defined as inappropriate diversity or distribution of species abundance for the age of the human. Dysbiosis in infants is driven by (1) the absence or deficiency of human milk oligosaccharides (HMO) due to the absence or deficiency of human breastmilk in the infant’s diet, (2) a gut microbiota that is deficient or absent in HMO metabolizing genes, or (3) the absence or deficiency of B. infantis, (or presence of B. infantis which is deficient in HMO-metabolizing genes, rendering it unable to completely metabolize HMO). For example, in an infant human, the level of keystone bacteria (e.g., Bifidobacteria, such as B. longum subsp. infantis) can be too low (e.g., deficient or absent) for the compete metabolism of all HMOs in human milk (for example, around 106cfu / g stool or less than 5% of the total gut microbiome). Dysbiosis can also be the elevated presence of members of the Enterobacteriaceae taxa (e.g., at a level that represents more than 20%, 30%, or 40% of the total gut microbiome).

[0105] “HUGs” are HMO utilization genes that can be expressed by any strain of bacteria in the gut. Most HUGs are identified in the Bifidobacterium taxa; however, other commensal bacteria can contribute to the overall function of degrading and metabolizing HMOs. Different genes from different bacteria in the metagenome are linked via annotated function through KEGG (available on the world wide web at genome.jp / kegg / ). The function and overall gene abundance within the ecosystem are features to consider. Table 1 provides the genes specifically from B. infantis, but other bacteria can contribute to this function and can be denoted according to the gene conventions for that organism but can be linked through annotated gene function. In some cases, genes from other bacteria 15  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT are at least 75% homologous to the Blon counterpart, at least 80%, at least 85%, at least 90% or at least 95%.

[0106] Table 1. HMO utilization genes (HUGS) in B. infantis. B. infantis specific gene clusters H1 H2 Fucosidase H3 H4 H5 Urease HMO cluster Fucosidase Sialic Acid Lacto-N-biose Cluster 4 5 6 7 8 9 0 1 2 3 4 5e ge es e e a e o . n an s e e o c us e s a ave ee annotated and relate to human milk oligosaccharide utilization and one cluster for urease utilization. Functionally equivalent genes from other Bifidobacterium or other genus, families, species of bacteria can contribute to the overall function for certain metabolic pathways deemed important in health or disease and the functions of carbohydrate transport, and / or HMO carbohydrate metabolism. A non- limiting example of other taxa that carry these HMO utilization genes include Bacteroidaceae, Enterobacteriaceae, Enterococcaceae, Eubacteriaceae, Clostridiaceae, Corynebacteriaceae, and Streptococcaceae.

[0108] In some embodiments, a deficiency (e.g., below a pre-determined threshold) of at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 50, 50, or more) HUG gene(s) indicates dysbiosis in the subject. In some embodiments, the term “amount of HUGs” refers to the reads per million of HUGs in a sequencing read. In some embodiments, the amount of HUGs represented in a sample is below a reference, e.g., at least 10% lower, at least 20% lower, at least 30% lower, at least 40% lower, at least 50% lower, at least 60% lower, at least 70% lower, at least 80% lower, at least 90% lower, at least 95% lower, at least 99% lower, or more, compared to a reference. In some embodiments, the 16  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT reference is a subject known not to be dysbiotic. In some embodiments relating to infants, the reference can refer to a subject in which B. infantis makes up at least 50% of the gut microbiome.

[0109] Table 2 includes NCBI Accession Numbers for HUG genes. In some embodiments, a HUG gene described herein encodes an amino acid sequence indicated by an accession numbered listed in Table 2 or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more, identical to an amino acid sequence indicated by an accession numbered listed in Table 2, that maintains its function. In some embodiments, a HUG gene described herein encodes an amino acid sequence that is at least 90% identical to an amino acid sequence indicated by an accession numbered listed in Table 2, that maintains its function. In some embodiments, a HUG gene described herein encodes an amino acid sequence that is at least 95% identical to an amino acid sequence indicated by an accession numbered listed in Table 2, that maintains its function. The term “maintains its function” as used herein refers to a variant polypeptide that retains at least 50% (e.g., at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more) of the wild-type reference polypeptide’s activity. The variant polypeptide can comprise conservative substitutions of the sequences disclosed herein (see e.g., Table 2). Nucleic acid sequence encoding the subject amino acid sequences are also available at NCBI.

[0110] Table 2: NCBI Accession Numbers for B. infantis ATCC 15697 genes of interest locus_tag gene_accession locus_tag gene_accessionBlon 0104 ACJ512331 Blon 0651 ACJ51758117 4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT locus_tag gene_accession locus_tag gene_accessionBlon_0641 ACJ51748.1 Blon_2348 ACJ53406.1Milk Oligosaccharides

[0111] Oligosaccharides having the chemical structure of the indigestible oligosaccharides found in any mammalian milk are referred to herein as “MMO” or “mammalian milk oligosaccharides” whether or not they are actually sourced from mammalian milk. HMO is a subset of all MMO. The term “human milk oligosaccharide” or HMO, as used herein, refers to all indigestible glycans found in mammalian human milk, sometimes referred to as “dietary fiber”, or the carbohydrate polymers that are not hydrolyzed by the endogenous mammalian enzymes and taken up in the digestive tract of the human. Human milk contains a significant quantity of HMO (about 15% of the macro- and micronutrient content combined) that is not usable directly as an energy source for the breast-fed infant but can be usable by many of the microorganisms in the gut of that infant. HMO can be found as free oligosaccharides (2–20 sugar residues) or they can be conjugated to, or previously released from, proteins or lipids (glycoproteins and glycolipids, respectively). Milk oligosaccharides can also be referred to as prebiotics or glycans. Oligosaccharides can be selected for its ability to selectively grow certain bacteria and / or suppress the growth of other bacteria. Such suppression can be through chemical means or as a consequence of ecological competition.

[0112] Particular oligosaccharides that can be found in HMO, and that can be administered as a prebiotic oligosaccharide or HMO, include, but are not limited to, one or more of: lacto-N-biose (LNB), N-acetyl lactosamine, lacto-N-triose, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), fucosyllactose (FL), lacto-N-fucopentaose (LNFP), lactodifucotetraose, (LDFT) sialyllactose (SL), disialyllacto-N-tetraose (DSLNT), 2'-fucosyllactose (2FL), 3’-sialyllactosamine (3SLN), 3'- fucosyllactose (3FL), 3'-sialyl-3-fucosyllactose(3S3FL), 3'-sialyllactose (3SL), 6'-sialyllactosamine (6SLN), 6'-sialyllactose (6SL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFPI), lacto-N- fucopentaose II (LNFPII), lacto-N-fucopentaose III (LNFPIII), lacto-N-fucopentaose V (LNFPV), sialyllacto-N-tetraose (SLNT), their derivatives, or combinations thereof. The major human milk oligosaccharides (“HMO”) include, but are not limited to, lacto-N-biose, lacto-N-tetraose (LNT), 18  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT lacto-N-neotetraose (LNnT) and lacto-N-hexaose, which are neutral HMOs, in addition to fucosylated oligosaccharides such as 2-fucosyllactose (2FL), 3-fucosyllactose (3FL), and lacto-N-fucopentaoses I, II and III. Acidic HMOs include sialyllacto-N-tetraose, 3′ and 6′ sialyllactose.

[0113] For the purposes of the instant disclosure, the HMO can be delivered in human milk or derivatives thereof such as, but not limited to, an expressed and / or stored portion of mother’s own milk, donor milk (frozen or pasteurized), reconstructed human milk, such as a human milk formula, a liquid or powder derived from human whey permeate or exempt infant formula, or from infant formula. Alternatively, HMO can be isolated and purified from human, bovine, or caprine milk. MMO for the compositions and methods described herein can also be sourced from recombinant microorganisms including, but not limited to bacteria and yeast.

[0114] In some embodiments, an appropriate concentration of HMO is delivered in a sterile liquid such as water. The HMO water is pre-mixed to have a concentration of 1 g / L, 2 g / L, 3g / L, 4 g / L, 8 g / L, 10 g / L, 12 g / L, 15 g / L, 20 g / L, 30 g / L or 40 g / L. An HMO water can be fed or administered throughout the day to reach a desired total dietary intake appropriate for the age and application used to prevent or treat a condition in a mammal.

[0115] In some embodiments, the MMO is selected from human milk oligosaccharides (HMO), and the HMO can comprise or consist of Lacto-N-tetraose (LNT) and / or Lacto-N-neotetraose (LNnT) and LNFP1. In some embodiments, the LNT and LNnT are in the range of 10:1, 4:3, 5:1, 2:1, 1:11:2, 3:4 or 1:10 ratio. In some embodiments, the HMO contains at least one sialic-acid-containing oligosaccharide structure that is not sialyl lactose, at least one fucose containing oligosaccharide that is not fucosyl lactose, and either LNT or LNnT. In some embodiments, the MMO has at least 2 MMOs selected from 2’FL 3’FL, 3’SL, 6’SL LNT, LNnT, DFL and LNFPI.

[0116] In some embodiments, galacto-oligosaccharides (GOS), fructooligosaccharides (FOS), polydextrose (PDX), or resistant starch is included in the composition. The ratio of GOS: MMO can be 1:20 to 20:1, or 1:10 to 10:1 ratio with any one of the MMO described herein. In some embodiments, the MMO comprises LNnT or a related structure and 2FL in 1:5 to 5:1 ratio. In some embodiments, the MMO comprises LNT or a structure related to LNT and 2’FL in 1:5 to 5:1 ratio. Other MMOs include but are not limited to trifucosyllacto-N-hexaose (TFLNH), LnNH, lacto-N- hexaose (LNH), lacto-N-fucopentaose III (LNFPIII), monofucosylated lacto-N-Hexose III (MFLNHIII), and Monofucosylmonosialyllacto-N-hexose (MFMSLNH). In some embodiments, the GOS has a degree of polymerization (DP) of larger than at least 4 (DP4), DP5 or DP6. In some embodiments, the DP4 is at least 30% of the total GOS provided. In some embodiments, D4 and D5 make up at least 50% of the GOS-containing composition. In some embodiments, the GOS has less than 10% DP3 (see e.g., WO 2010 / 105207, published September 16, 2010, which is incorporated herein by reference in its entirety). In some embodiments, a ratio of GOS / FOS, GOS / inulin, GOS / FOS / inulin, GOS / PDX is used with one or more mammalian milk oligosaccharides. In other embodiments, GOS, FOS, inulin, and / or PDX are expressly excluded from compositions or from the 19  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT diet. The dietary intake of total milk oligosaccharides regardless of source can be calculated, such that a typical infant receives at least 0.5 g of MMO per day, at least 2 g per day, at least 4 g / per day, at least 6 g / per day, at least 8 g per day at least 10 g per day, at least 12 g per day, at least 15 g / per day or at least 20 g / per day.

[0117] In some embodiments, the added total dietary milk oligosaccharides can come from a combination of partially purified oligosaccharide from human milk products, human donor milk, bovine, caprine, or human or bovine glycoproteins, and / or synthetic single source. Human milk products modified through processes such as skimming, protein separation, pasteurization, retort sterilization can also be a source of MMO for use in any composition described herein. Such human milk products can be separated from the mother’s own milk during breast feeding. Bacterial Compositions

[0118] A medicament with Bifidobacterium species can be described as a bacterial composition, as a live biotherapeutic, dietary supplement or a food, a food for special dietary use (FSDU), or a medical food. In one embodiment, the bacterial composition is a Live Biotherapeutic (LBT). A live biotherapeutic is a biological product that: 1) contains live organisms, such as bacteria; 2) is applicable to the prevention, treatment, or cure of a disease or condition of human beings; and 3) is not a vaccine. A bacterial composition administered to affect hematochezia in preterm infants, FPIAP, FPE or FPIES whether or not explicitly stated as a means to prevent or treat such conditions is covered by the methods and compositions disclosed herein.

[0119] In some embodiments, the bacteria (e.g., Bifidobacterium) a supernatant generated during fermentation of the bacteria (e.g., Bifidobacterium) can also be administered, including, but is not limited to, a metabolite, an energy source or other factor important for bacterial function (see e.g., Tables 6-7).

[0120] The bacteria used in the compositions and methods described herein can be selected from any Bifidobacterium species and strain that has the capability of metabolizing at least 50% of the HMO structures found in human milk. As used herein, the phrase “is capable of metabolizing” refers to encoding and expressing genes that direct the synthesis of enzymes necessary for metabolizing a given HMO substrate.

[0121] In one embodiment, the Bifidobacterium used in the methods and compositions described herein can be in an activated state as defined by the expression of genes coding for enzymes or proteins such as, but not limited to, fucosidases, sialidases, extracellular glycan binding proteins, and / or sugar permeases. Such an activated state is produced by the cultivation of the bacteria in a medium comprising a MMO prior to harvest and the preservation and drying of said bacteria as described, for example, in US Patent 10,716,816, the content of which is incorporated herein by reference in its entirety. 20  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT

[0122] Non-limiting examples of Bifidobacterium that can be used for the composition of the medicaments, methods and compositions described herein include but are not limited to qualifying strains of Bifidobacterium breve, Bifidobacterium longum subsp longum, Bifidobacterium longum subsp infantis, Bifidobacterium longum subsp suis, Bifidobacterium pseudolongum, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Bifidobacterium catenulatum, Bifidobacterium bifidum, and Bifidobacterium dentium. In one embodiment, an H5-positive strain of B. infantis is used (see e.g., Table 1). In one embodiment, B. infantis strain EVC001 or ATCC strain 15697 is used. In another embodiment, B. infantis strain INF108 is used. In one embodiment, B. infantis EVC001 strain or B. infantis strain INF108 is used in its activated state.

[0123] In some embodiments, the Bifidobacterium present can be an activated Bifidobacterium culture and can be dried prior to administration (see, e.g., WO 2016 / 065324 published April 28, 2016 and WO 2019 / 143871 published July 25, 2019, incorporated herein by reference). In some embodiments, the Bifidobacterium present, activated or otherwise, is B. infantis EVC001 deposited under ATCC Accession No. PTA-125180. In some embodiments, the B. infantis is an H5 positive strain or a strain with a fully functional H5 gene cluster in its genome. The H5 positive strain refers to the ability of the strain to transport and use certain oligosaccharide structure (see e.g., WO 2019 / 232284; see e.g., Table 1). In some embodiments, the B. infantis or other live bacterium have specific enzymes, such as or equivalent in function to, EndoBI-1 and / or EndoBI-2 (N-linked endoglycosidases found in B. infantis) to cleave glycans from whey protein in vivo.

[0124] In some embodiments, the bacteria (e.g., B. infantis) is activated with an activator, in order to increase expression of HUG genes and / or H5 cluster genes. An activator is able to induce expression of genes in an organism but does not necessarily promote the selective growth of the organism over other organisms during an in vivo or an in vitro competition assay.

[0125] An “activated cell” is defined as one that has an increased expression in at least one of the genes found in the HMO clusters in B. infantis, or functionally homologous genes in other bacterial species. The activated cell can show increased expression of solute binding proteins (SBP), extracellular enzymes, or ABC transporters on the cell surface or the activation change can be intracellular.

[0126] In some embodiments, activation is considered to be when the relative expression of the HMO cluster genes is upregulated compared to the same genes when the cell is grown on lactose or glucose. The genes selected for activation are known to be upregulated when grown in the presence of MMO compared to lactose or glucose, so if their expression is increased relative to the reference gene, it is sufficient to describe activation. In some embodiments, gene activation relates to Blon_0881 and Blon_2343, and their expression is greater than 1; that is, when the delta delta cycle threshold (2−ΔΔCt) is greater than 1, 2−ΔΔCtis calculated using Blon_0393, or another constitutively expressed gene as a reference. The result (activation) is the fold change (2−ΔΔCt> 1) of gene expression, determined based on the 2−ΔΔCtmethod (see e.g., Livak K and Schmittgen T. Methods 21  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT 25(4):402-8 (2001), the contents of which are incorporated herein by reference in their entirety). In some embodiments, other genes from Table 1 are used in addition to Blon_0881 and Blon_2343.

[0127] In some embodiments, activation of Bifidobacterium infantis cells can require upregulation of Blon_0881 (glucosamine-6-phosphate isomerase) and Blon_2343 (carbohydrate ABC transporter membrane protein) and / or homologues of glucosamine-6-phosphate isomerase and carbohydrate ABC transporter membrane protein from other Bifidobacterium, Lactobacillus and Pediococcus (Blon_0881, Blon_2343, Bon_0393; see e.g., Table 3 in WO 2019 / 143871), and activation can be confirmed by monitoring expression of these genes. In other embodiments, an additional gene is selected from one of the clusters listed in Table 1 (or Table 2 in WO 2019 / 143871; e.g., Blon_0882, Blon_0881, Blon_0880, Blon_0789), or its functional homologues in other species. In some embodiments, activation is alternatively measured using one or more genes that are not Blon-0881 or Blon_2343 or its species-specific functional homologues. In some embodiments, activation of the HMO phenotype involves upregulation of a transcriptional regulator, such as Blon_0042 from B. infantis. In some embodiments, activation genes can be selected from one or more of Blon_R0015, Blon_R0017, Blon_R0021, Blon_R0022, which are transfer RNA (tRNA) of the amino acids valine, leucine, phenylalanine, and aspartate, respectively. In some embodiments, activation can involve monitoring downregulation of Blon_0518, Blon_0785 (ABC- type nitrate / sulfonate / bicarbonate transport system, periplasmic component), Blon_2167 (hypothetical protein), and / or Blon_2168 (phage shock protein C (PspC) family protein).

[0128] In some embodiments, Akkermansia species or Lactobacillus species (name changed to Lacticaseibacillus or Limosilactobacillus, but for purposes here either can be used). Akkermansia species can be selected from Akkermansia muciniphila or Akkermansia glycaniphila. Lactobacillus species can be selected from Lactobacillus crispatus, Lactobacillus johnsonii, Lacticaseibacillus rhamnosus, Limosilactobacillus reuteri, and Lacticaseibacillus paracasei. Vitamins

[0129] In some embodiments, the bacterial medicaments described herein (e.g., Bifidobacterium LBT) can further comprise at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) vitamins. Vitamins are substances that the body cannot synthesize yet needs to grow and develop normally. There are 6 primary vitamin families that humans need. These primary vitamins include Vitamin A (retinol, carotenoids), Vitamin B (thiamine, riboflavin, niacin, niacinamide, pantothenic acid, pyridoxine, pyradoxamin, pyridoxal, biotin, folic acid, folate, folic acid, cyanocobalamin, hydroxocobalamin, methylcarbylamine), Vitamin C (ascorbic acid), Vitamin D (cholecalciferol, ergocalciferol), Vitamin E (tocopherols, tocotrienols), and Vitamin K (phylloquinone, menaquinone). Any of these Vitamins can be combined with the bacterial composition (e.g., Bifidobacterium LBT) and can be used in these compositions to treat or prevent FPIAP and / or FPIES. 22  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT DHA forms and sources

[0130] In some embodiments, the bacterial composition described herein (e.g., Bifidobacterium LBT) can further comprise docosahexaenoic acid (DHA). DHA is a long chain polyunsaturated fatty acid that is a primary building block of human brain tissue. Sources of DHA include fish oil, algal oil, and oil from recombinant plants or microorganisms. Biological sources of DHA are generally found in a triglyceride or phospholipid form. These sources of DHA can provide a starting material for purer forms of DHA such as free fatty acids (by saponification) or methyl, ethyl, or propyl esters or structured monoglycerides, diglycerides or triglyceride (by transesterification). All forms of DHA including, but not limited to, triglyceride, phospholipid, free fatty acids or methyl, ethyl or propyl esters can be used in the methods and compositions described herein. Medicaments

[0131] In some embodiments, the medicament LBT is comprised of Bifidobacterium. In some embodiments, one or more Bifidobacterium species is selected for its overall contribution to HUGs. The Bifidobacterium can be selected from, but not limited to, the following species: B. adolescentis, B. bifidum, B. breve, B. catenulatum, B. longum, B. longum subsp. infantis (B. infantis), B. longum subsp. longum (B. longum), B. longum subsp. suis. B. pseudocatanulatum, and B. pseudolongum. The Bifidobacterium species or subspecies can be selected from the group that are typically associated with infants, such as B. infantis, B. breve and / or B. bifidum. The selection of specific strains within a species can be made based on overall contribution to the gene functions related to H1, H2, H3, H4, H5 or urease clusters. In some embodiments, functions relate to genes to at least one of Blon0243, Blon0625, Blon2171, Blon2174, Blon2175, Blon2176, and Blon2177. In some embodiments, a rational consortium of other glycosylhydrolases can be considered when determining consortium members that will increase certain metabolites to support overall function of microbiome and contribute to metabolic pathways supported by HUG activities.

[0132] In some embodiments, the medicament comprises at least one bacterium expressing at least (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 50, 50, or more) HUGs. A non-limiting example of taxa other than Bifidobacterium that carry these HMO utilization genes include Bacteroidaceae, Enterobacteriaceae, Enterococcaceae, Eubacteriaceae, Clostridiaceae, Corynebacteriaceae, and Streptcoccacaeae. In some embodiments, the medicament comprises at least one bacterium engineered to express one or more HUGs.

[0133] It is contemplated that rather than a single bacterium, two or more bacterial strains, each expressing one or more of the genes in gene cluster H5, or homologous to genes in gene cluster H5, can be administered. In this embodiment, the enzymes expressed in the two or more bacterial strains together comprise the function encoded by gene cluster H5 that permits the uptake and metabolism of human HMOs. In one embodiment, at least one of the two or more bacterial strains, or two or more of the bacterial strains are Bifidobacterial strains. In another embodiment, all of the two or more 23  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT bacterial strains are Bifidobacterial strains. In another embodiment, none of the two or more bacterial strains are Bifidobacterial strains; it is contemplated that one or more of the bacterial strains can be engineered to express one or more of the genes in, or analogous to genes in, gene cluster H5.

[0134] In one embodiment of the compositions and methods described herein, the medicament comprises one or more Bifidobacterium species. In one embodiment, the medicament comprises B. infantis. In one embodiment, the medicament LBT comprises B. infantis EVC001. In one embodiment, the medicament LBT comprises activated B. infantis EVC001. In one embodiment, the LBT is provided at a daily dose of from 107to 1011cfu, 108to 109.5cfu, or 109to 1010cfu per daily dose which can be delivered in a single or multiple doses throughout the day. In some embodiments, the medicament (e.g., LBT) is provided in a dose as low as 10 or 100 cfu, e.g., at least 101cfu, at least 102cfu, at least 103cfu, at least 104cfu, at least 105cfu, at least 106cfu, at least 107cfu, at least 108cfu, at least 109cfu, at least 1010cfu, at least 1011cfu, 101to 102cfu, 102to 103cfu, 103to 104cfu, 104to 105cfu, 105to 106cfu, 106to 107cfu, 107to 108cfu, 108to 109cfu, 109to 1010cfu, 1010to 1011cfu, 107to 1011cfu, 108to 109.5cfu, or 109to 1010cfu, or 1011to 1013per dose of bacteria, which can be delivered in a single or multiple doses. The live bacterium can be present in 0.1 million to 500 billion colony forming units (CFU) per serving, per gram, per ml or per unit dose of the composition. In some embodiments, the bacterium is present as 1 million to 100 billion CFU or 5 million to 50 billion CFU per serving, per gram, per ml or per unit dose of the composition.

[0135] In some embodiments, the medicament (e.g., LBT) is provided in a single dose. In some embodiments, the medicament (e.g., LBT) is provided as multiple doses. The dosage of a composition as described herein can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment. With respect to duration and frequency of treatment, it is typical for skilled clinicians to monitor subjects in order to determine when the treatment is providing therapeutic benefit, and to determine whether to increase or decrease dosage, increase or decrease administration frequency, discontinue treatment, resume treatment, or make other alterations to the treatment regimen. The dosing schedule can vary from once a week to daily depending on a number of clinical factors, such as the subject's sensitivity to the bacterial composition. The desired dose or amount can be administered at one time or divided into subdoses, e.g., 2-4 subdoses and administered over a period of time, e.g., at appropriate intervals through the day or other appropriate schedule. In some embodiments, administration can be chronic, e.g., one or more doses and / or treatments daily over a period of weeks or months. Examples of dosing and / or treatment schedules are administration 1-12 times per day over a period of 1 day, 3 days, 5 days,1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months, or more. The medicament can be administered added to a food before consumption, added to water between meals or other infant feeding protocols.

[0136] In another embodiment of the compositions and methods described herein, the medicament is comprised of Bifidobacterium and one or more HMOs. In one embodiment, the medicament comprises Bifidobacterium and one or more HMOs. In one embodiment, the HMO 24  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT component of the medicament comprises one or more of LNB, LNT, LNnT, 2FL, 3SL, and LNFP. In another embodiment, the medicament comprises from 0.5g-40 g HMO, 1g-20g HMO, 2g-10g HMO, or 3g-5g HMO per daily dose, which can be delivered in a single or multiple doses, separately or contemporaneously with the LBT throughout the day.

[0137] In another embodiment of the compositions and methods described herein, the medicament is comprised of the LBT and one or more vitamins. In one embodiment, the medicament comprises the LBT and one or more vitamins. In one embodiment, the vitamin component of the medicament comprises one or more of Vitamin A, Vitamin D, and vitamin E. In another embodiment, the medicament comprises from 100 µg - 800 µg Vitamin A, 5 µg - 25 µg Vitamin D, and / or 10 µg - 50 µg Vitamin E per daily dose, which can be delivered in a single or multiple doses, separately or contemporaneously with the LBT throughout the day.

[0138] In another embodiment of the compositions and methods described herein, the medicament is comprised of the LBT and DHA in one or more forms from one or more sources. In one embodiment, the medicament comprises the LBT and DHA in one or more forms from one or more sources. In one embodiment, the DHA of the medicament comprises DHA predominantly in a triglyceride form and / or from a source that contains little or no eicosapentaenoic acid (EPA) such as, but not limited to, an algal oil or a restructured triglyceride. In one embodiment, the medicament comprises from 1 mg - 50 mg DHA, 5 mg - 40 mg DHA, 8 mg - 30 mg DHA, or 10 mg - 20 mg per daily dose, which can be delivered in a single or multiple doses, separately or contemporaneously with the LBT throughout the day.

[0139] In another embodiment of the compositions and methods described herein, the medicament comprises an LBT plus HMO plus at least one vitamin. In another embodiment, the medicament comprises an LBT plus DHA plus at least one vitamin. In another embodiment, the medicament comprises an LBT plus HMO plus DHA. In another embodiment, the medicament comprises an LBT plus HMO plus at least one vitamin plus DHA.

[0140] In some embodiments, the medicaments, compositions, and / or formulations comprise B. infantis and / or MMO and one or more allergenic proteins, such as those from milk, egg, soy, wheat, shellfish, tree nut, peanut, fish or sesame, that are known to cause allergic reactions in susceptible individuals. In some embodiments, the amount of allergen is less than 1 mg, less than 5 mg, less than 10 mg, less than 20 mg, less than 30 mg, less than 40mg, less than 50 mg, less than 60 mg, less than 100 mg or more than 100 mg. In some embodiments, the allergen is added in increasing amounts over time or in stages wherein the diet is specified to the amount of allergen provide as a total daily intake. Delivery of Medicament

[0141] In one embodiment of the compositions and methods described herein, the medicament is provided to the patient or subject in a powder form that is mixed with or dissolved in human milk or infant formula and provided to the infant through oral means. The powder form can include fillers, 25  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT diluents, or binders known to the industry such as, but not limited to lactose, maltodextrin, inulin, sucrose, trehalose, pea protein, milk fat globule membrane, glycomacropeptide, starches, polyols (e.g., sorbitol, mannitol, etc.), cellulose (e.g., microcrystalline cellulose, etc.), etc.

[0142] In another embodiment of the compositions and methods described herein, the medicament is provided to the patient or subject in an oil form that is mixed with, or dissolved in human milk or infant formula, or added directly to the infant’s lips or mouth or by an enteral feeding. The oil form can include diluents known to the industry such as, but not limited to vegetable oil, medium chain triglyceride oil, etc. Excipients and other components that increase functionality of the formulation include different types of ingredients and applications, such as but not limited to: oils including but not limited to MCT, Olive, Sunflower, Rice Bran, Mineral, docosahexaenoic acid (DHA) or arachidonic acid (ARA)-containing oils; fat soluble vitamins, such as but not limited to Vitamins: D3 (powder and liquid), E (Alpha tocopherol), K (K1 or K2), Vitamin A or its precursors or derivatives; and oligosaccharide-based ingredients such as but not limited to FOS, GOS, Lactose, 2-FL, LNT, LNnT, LNFPl, 3SL, 6SL, Maltodextrin, Microcrystalline cellulose. Formulations can include unguents, such as lanolin, super refined petroleum jelly, Anhydrous Milk Fat (AMF), TOPCITHIN SF (sunflower lecithin), Lacprodan milk fat globule membrane (MFGM) or any derivative of MFGM, and / or amino acids such as tryptophan, whey protein, or whey peptides that are or are not glycosylated.

[0143] In some compositions, the live bacteria are dried and then suspended in an oil, such as a MCT oil or other oils described herein. The oil can further comprise DHA and / or ARA, and / or fat- soluble vitamins, such as a vitamin A, provitamin A and / or Vitamin D.

[0144] Other embodiments of the compositions and methods described herein can provide the medicament in the form of a suspension or a paste that can be provided directly to the subject’s (e.g., infant’s) lips or mouth.

[0145] Other embodiments can include, but are not limited to, where the form is a powder; a gel; a liquid suspension; a paste; a butter (e.g., nipple butter); a cream (e.g., nipple cream); an oil; a foam; a dissolvable laminated sheet or tablet form; or a gel capsule. The medicament can be delivered orally, or rectally as a suppository or enema. Selection of patient population and evaluation of treatment efficacy

[0146] In some embodiments, the patient population is selected based on onset of symptoms (i.e., Blood stools, vomiting, profuse vomiting, GERD, APGAR scores, excessive crying, low anthropometric scores, poor cognitive scores, high level of enteric or systemic inflammation (i.e., > 200ug / mg fecal calprotectin)).

[0147] In one embodiment of the compositions and methods described herein, a patient or subject with FPIAP is identified by one or more of: 1) detectable blood in the stool; 2) a gut dysbiosis as identified by less than 5% of the gut microbiome comprising B. infantis and / or over 20-40% of the 26  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT gut microbiome as Enterobacteriaceae; 3) elevated biomarkers of chronic gut inflammation including, but not limited to GM-CSF, TARC, IL-1β, IL-17α, IL-31, TNFα, and INFβ; 4) 5-7 watery or mucoid stools; and / or 5) incomplete metabolism of HMO resulting in intact HMO passage into the stool.

[0148] In one embodiment, following administration of the compositions described herein, the microbiome function changes such that the relative abundance of the Bifidobacterium family (Bifidobacteriaceae) increases in the subject. In such embodiments, the Bifidobacterium population can increase to at least 25%, at least 30%, at least 40%, at least 50%, at least 65%, at least 75%, at least 85%, or at least 90% of the total gut microbiome; whereas in other embodiments, the Enterobacteriaceae decreases to less than 30%, less than 20%, less than 15%, less than 10%, less than 5%, or less than 1% of the total gut microbiome. In some embodiments, following administration of the compositions described herein, the abundance or copy number (counts per million) of HUG genes increases. In such embodiments the increase in HUG genes can be by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%.70%, 75%, 80%, 85% or at least 95%, or by 1x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, or more. In some embodiments, following administration of the compositions described herein, the availability of specific metabolites (e.g., bacterial metabolites) increases. In such embodiments the increase of specific metabolites (e.g., bacterial metabolites) can be by at least 1%, 5%, 10%, 25%, 50%, 75%, 100%, 200%, or more than 200%, or by 1x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, or more.

[0149] As used herein, the term “elevated stool inflammatory markers” refers to levels of the recited markers at least 10% higher, at least 20% higher, at least 30% higher, at least 40% higher, at least 50% higher, at least 60% higher, at least 70% higher, at least 80% higher, at least 90% higher, at least 1 fold higher, at least 2-fold higher, at least 3-fold higher, at least 4-fold higher, at least 5-fold higher or more relative to a healthy control. In some embodiments, the stool inflammatory markers are selected are GM-CSF, TARC, MIP-1B, MCP-1, MCP-4, VEGF, IL-13, MIP-3a, IL-17A, IL-21, IL-1a, IL-33, IL-1β, IL-17α, IL-31, TNFα, and INFβ.In some embodiments, the stool inflammatory markers comprise eotaxin.

[0150] Resolution of symptoms and / or efficacy of the composition and methods described herein can be measured by: 1) lack of blood in the stool; 2) B. infantis colonization of the gut representing over 50%, over 60% over 70%, over 80%, or over 90% of the total of the gut microbiome; 3) Enterobacteriaceae levels dropping to less than 50%, less than 40%, less than 30%, less than 20%, less than 10% of the total of the gut microbiome; 4) levels of gut proinflammatory biomarkers including, but not limited to GM-CSF, TARC, MIP-1B, MCP-1, MCP-4, VEGF, IL-13, MIP-3a, IL- 17A, IL-21, IL-1a, IL-33, IL-1β, IL-17α, IL-31, TNFα, and INFβ, dropping by over 50%, over 60%, over 70%, over 80%, over 90%; 5) stooling patterns reaching 1-2 well formed stools / day; and / or 6) complete digestion of HMO such that intact HMO is reduced by from 50% to 99%, or undetectable in the stool of affected and treated infants. 27  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT

[0151] Some embodiments of the methods described herein comprise modifying the gut microbiome function. This modification can include increasing absolute and / or relative expression of HUG genes or otherwise increasing the HUG gene product levels, including increased abundance or amount of the gene which can, for example, be measured in counts per million reads, or as copy number of a gene of interest. These are methods in which one can quantify genetic potential within a fecal sample to assess microbiome function. High copy number or high counts per million reads can be a sign of a high functioning microbiome for HUGs. Conversely, low copy number or low counts per million can signify a deficiency of function. In some embodiments, the HUG genes selected for expression modification can include one or more of Blon_0243, Blon_2171, Blon_2174, Blon_2175, and Blon_2176. In some embodiments, the expression of the Blon_0625 gene increases. In some embodiments, HUG expression can be modified at least in part by administration of MMO.

[0152] Therapeutic treatment utilizing some embodiments as describe herein can result in decreased Enterobacteriaceae abundance in the individual’s gut. Some embodiments can result in increased relative HUG abundance. In some embodiments, a change in microbiome function can be further measured by lower gut pH, metagenomic sequencing, absence or presence of specific metabolites coded by HUGs, and / or decreased enteric and systemic inflammatory biomarkers. Such an enteric and systemic inflammatory biomarker can be interferon beta and / or Galectin-1.

[0153] The microbiome function can be quantified based on sequenced and annotated genetic material and relative level of those identified genetic sequences, protein expression levels of said sequences and / or metabolic output in that fecal sample. In one embodiment, the fecal sample is analyzed, and quantification comprises at least one of the following methods: metagenomics, transcriptomics, proteomics, metabolomics analyses, ELISA, PCR, Western blot, and / or enzyme assay.

[0154] Specific metabolites can be delivered directly or indirectly to a patient in need to train the immune system (i.e., immunological imprinting). Indirect delivery can mean supplying a precursor substrate in the metabolic pathway to drive the overall system to produce the specific metabolite. Alternatively, the key metabolite can be produced in vivo through chemical or microbial transformation. The metabolites can be delivered directly to the gut in a form that reaches a desired location with the gastrointestinal tract. Metabolites at therapeutic concentrations can be delivered orally by mouth or rectally in a suppository or enema preparation.

[0155] In some embodiments, a fecal sample from an infant is evaluated for the copy number of certain HMO utilization genes considered protective against food allergy, and above this number egg and milk allergens can be introduced at a desensitizing level and steadily increased over time.

[0156] Copy number can be evaluated using a bioinformatics approach using next generation sequencing that provides redundant coverage and long reads. Another approach can use qPCR for expression of certain proteins. 28  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT

[0157] Specific metabolites of interest (e.g., indole-3-lactic acid) can be quantified in biological samples to ensure specified concentration is reached to ensure impact on immune cell development.

[0158] Treatment can be initiated for individuals whose HMO score falls below the threshold – treatment is given to increase the functional capacity above the threshold. Treatment can involve the use of Bifidobacterium and / or Human milk oligosaccharides. HMO thresholds can be adjusted for the age of patient, according to levels of HMOs in a healthy control of the same age.

[0159] A second fecal sample can be collected (e.g., after starting the treatment regimen) to verify that the functional capacity has changed to a new profile before the introduction of an allergen to the diet.

[0160] The level of allergen can be titrated up or down to produce tolerance to said allergen.

[0161] In one embodiment, the production and purification of small molecules from a fermentation system is used to produce mixtures of metabolites in certain ratios from the bacterial fermentation supernatant. The development of individual metabolites that are tested alone and in specific combinations and ratios can be developed as a drug cocktail. In some embodiments, the bacterial metabolites can be delivered through capsules, gels, powders, liquid, or by pill form to reach a targeted part of the intestinal tract. The bacterial metabolite(s) can be delivered orally or rectally. The bacterial metabolite(s) can take the form of a powder, an oil suspension, gel, or a liquid. The bacterial metabolite(s) can be a loose powder (in a sachet or package), in a tablet, in a dissolving tablet, or in a capsule or integrated in a nutritional source depending on the application. The bacterial metabolite(s) can be administered as an enema or suppository.

[0162] In some embodiments, treatment is monitored for persistent colonization above a threshold that alleviates symptoms related to childhood immune-related disorders and diseases (e.g., symptoms: Anemia, Eczema, wheeze, GERD, bloody stools, vomiting or profuse vomiting, abdominal distention, frequent stooling, low anthropometric scores, excessive crying).

[0163] In some embodiments, HUGs abundance is monitored in relation to Enterobacteriaceae, or in evaluated by biochemical changes in the gut (e.g., Lower pH), metagenomic sequencing, absence of presence of specific metabolites coded by HUGs, and / or decreased enteric and / or systemic inflammatory biomarkers.

[0164] In one embodiment, the subject is an infant, and can be, for example, a term or pre-term infant, an infant in a neonatal intensive care unit (NICU) or an infant at home. In one embodiment, the subject with hematochezia has FPIAP or FPIES.

[0165] In some embodiments, the patient or subject, or population thereof, is selected from an infant less than 3 months of age. A preterm infant can be described by gestational age less than 33 week, as extremely low birth weight (ELBW) or less than 1000 grams, very low birth weight (VLBW) or less than 1500g, low birth weight. The infant can be a term infant – age 0-3 months, 0-6 months, 6-12 months, 21-24 months or 0-24 months. 29  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT

[0166] In some embodiments, hematochezia is associated with or predisposes an individual for later development of allergies.

[0167] In some embodiments, the mother is given a treatment regime in the 3rdtrimester and / or the fourth trimester (i.e., postpartum period starting from the infant’s birth until the infant turns 3 months old. In some embodiments, mother and infant are both treated. In some embodiments, only the infant is treated. In some embodiments, only the mother is treated. Definitions

[0168] For convenience, the meaning of some terms and phrases used in the specification, examples, and appended claims, are provided below. Unless stated otherwise, or implicit from context, the following terms and phrases include the meanings provided below. The definitions are provided to aid in describing particular embodiments, and are not intended to limit the claimed invention, because the scope of the invention is limited only by the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. If there is an apparent discrepancy between the usage of a term in the art and its definition provided herein, the definition provided within the specification shall prevail.

[0169] As used herein, a “source of DHA” refers to a substance which contains or releases DHA at a therapeutically effective level or in a therapeutically effective amount.

[0170] As used herein, the term “functional,” when applied to a gene or gene cluster means that the gene or gene cluster includes genetic control elements and linked coding sequences that permit transcription and translation of relevant genes in the cluster to produce, under relevant conditions or circumstances (e.g., in the gut of an infant) the relevant gene products, and that those gene products carry out the relevant function. As a non-limiting example, a “functional” H5 gene cluster that transports and metabolizes lacto-N-biose HMO derivatives present in human milk permits transcription and translation of H5 gene cluster genes that permit transport of the lacto-N-biose HMO derivatives in human milk into, and metabolism by, the bacterial cell encoding the gene cluster, in the gut of an infant.

[0171] As used herein, the term “capable of expressing” refers to the combination of sequences encoding specified genes or gene products with control elements that direct such sequences to be transcribed and translated. In some embodiments, the control elements direct transcription and translation under a particular set of physiologically relevant circumstances, e.g., conditions found in the mammalian infant gut.

[0172] The terms “decrease”, “reduced”, “reduction”, or “inhibit” are all used herein to mean a decrease by a statistically significant amount. In some embodiments, “reduce,” “reduction" or “decrease" or “inhibit” typically means a decrease by at least 10% as compared to a reference level (e.g. the absence of a given treatment or agent) and can include, for example, a decrease by at least 30  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99% , or more. As used herein, “reduction” or “inhibition” does not encompass a complete inhibition or reduction as compared to a reference level. “Complete inhibition” is a 100% inhibition as compared to a reference level. A decrease can be down to a level accepted as within the range of normal, e.g., for an individual without a given disorder.

[0173] The terms “increased”, “increase”, “enhance”, or “activate” are all used herein to mean an increase by a statically significant amount. In some embodiments, the terms “increased”, “increase”, “enhance”, or “activate” can mean an increase of at least 10% as compared to a reference level, for example an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a 100% increase or any increase between 10-100% as compared to a reference level, or at least about a 2-fold, or at least about a 3-fold, or at least about a 4-fold, or at least about a 5-fold or at least about a 10-fold increase, or any increase between 2-fold and 10-fold or greater as compared to a reference level. In the context of a marker or symptom, an “increase” is a statistically significant increase in such level.

[0174] As used herein, a "subject" means a human or animal. Usually the animal is a vertebrate such as a primate, rodent, domestic animal or game animal. Primates include chimpanzees, cynomolgus monkeys, spider monkeys, and macaques, e.g., Rhesus. Rodents include mice, rats, woodchucks, ferrets, rabbits and hamsters. Domestic and game animals include cows, horses, pigs, deer, bison, buffalo, feline species, e.g., domestic cat, canine species, e.g., dog, fox, wolf, avian species, e.g., chicken, emu, ostrich, and fish, e.g., trout, catfish and salmon. In some embodiments, the subject is a mammal, e.g., a primate, e.g., a human. The terms, “individual,” “patient” and “subject” are used interchangeably herein.

[0175] In some embodiments, the subject is a mammal. The mammal can be a human, non- human primate, mouse, rat, dog, cat, horse, or cow, but is not limited to these examples. Mammals other than humans can be advantageously used as subjects that represent animal models of dysbiosis, FPIAP, and / or FPIES. A subject can be male or female.

[0176] A subject can be one who has been previously diagnosed with or identified as suffering from or having a condition in need of treatment (e.g. FPIAP and / or FPIES) or one or more complications related to such a condition, and optionally, have already undergone treatment for FPIAP and / or FPIES or the one or more complications related to FPIAP and / or FPIES. Alternatively, a subject can also be one who has not been previously diagnosed as having FPIAP and / or FPIES or one or more complications related to FPIAP and / or FPIES. For example, a subject can be one who 31  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT exhibits one or more risk factors for FPIAP and / or FPIES or one or more complications related to FPIAP and / or FPIES or a subject who does not exhibit risk factors.

[0177] A “subject in need” of treatment for a particular condition can be a subject having that condition, diagnosed as having that condition, or at risk of developing that condition.

[0178] In some embodiments, the patient or subject, or population thereof, is selected for treatment based on onset of symptoms (e.g., bloody stools, IgE antibodies, autoantibodies, excessive crying, low anthropometric scores, poor cognitive scores, high level of enteric or systemic inflammation (e.g., > 200ug / mg fecal calprotectin).

[0179] A variant amino acid or DNA sequence can be at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more, identical to a native or reference sequence. The degree of homology (percent identity) between a native and a mutant sequence can be determined, for example, by comparing the two sequences using computer programs commonly employed for this purpose freely available on the world wide web (e.g. BLASTp or BLASTn with default settings).

[0180] A variant amino acid sequence can be at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more, similar to a native or reference sequence. As used herein, “similarity” refers to an identical amino acid or a conservatively substituted amino acid, as described herein. Accordingly, the percentage of “sequence similarity” is the percentage of amino acids which is either identical or conservatively changed; e.g., “sequence similarity” = (% sequence identity)+(% conservative changes). It should be understood that a sequence that has a specified percent similarity to a reference sequence necessarily encompasses a sequence with the same specified percent identity to that reference sequence. The skilled person will be aware of various computer programs, using different mathematical algorithms, that are available to determine the identity or similarity between two sequences. For instance, use can be made of a computer program employing the Needleman and Wunsch algorithm (Needleman et al. (1970)); the GAP program in the Accelrys GCG software package (Accelerys Inc., San Diego U.S.A.); the algorithm of E. Meyers and W. Miller (Meyers et al. (1989)) which has been incorporated into the ALIGN program (version 2.0); or the BLAST (Basic Local Alignment Tool using default parameters); see e.g., US Patent 10,023,890, the content of which is incorporated by reference herein in its entirety.

[0181] In some embodiments, sequencing comprises 16S rRNA gene sequencing, which can also be referred to as “16S ribosomal RNA sequencing”, “16S rDNA sequencing” or “16s rRNA sequencing”. Sequencing of the 16S rRNA gene can be used for genetic studies as it is highly conserved between different species of bacteria, but it is not present in eukaryotic species. In addition to highly conserved regions, the 16S rRNA gene also comprises nine hypervariable regions (V1-V9) that vary by species.16S rRNA gene sequencing typically comprises using a plurality of universal primers that bind to conserved regions of the 16S rRNA gene, PCR amplifying the bacterial 16S 32  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT rRNA gene regions (including hypervariable regions), and sequencing the amplified 16S rRNA genes with a next-generation sequencing technology as described herein (see also e.g., US Patents 5,654,418; 6,344,316; and 8,889,358; and US Patent Application Numbers US 2013 / 0157265 and US 2018 / 0195111, which are incorporated by reference in their entireties).

[0182] "Marker" in the context of the present disclosure refers to an expression product, e.g., nucleic acid or polypeptide which is differentially present in a sample taken from subjects having FPIAP and / or FPIES, as compared to a comparable sample taken from control subjects (e.g., a healthy subject). The term "biomarker" is used interchangeably with the term "marker."

[0183] In some embodiments, the methods described herein relate to measuring, detecting, or determining the level of at least one marker. As used herein, the term "detecting" or “measuring” refers to observing a signal from, e.g. a probe, label, or target molecule to indicate the presence of an analyte in a sample. Any method known in the art for detecting a particular label moiety can be used for detection. Exemplary detection methods include, but are not limited to, spectroscopic, fluorescent, photochemical, biochemical, immunochemical, electrical, optical or chemical methods. In some embodiments of any of the aspects, measuring can be a quantitative observation.

[0184] In some embodiments of any of the aspects, a polypeptide, nucleic acid, or cell as described herein can be engineered. As used herein, “engineered" refers to the aspect of having been manipulated by the hand of man. For example, a polypeptide is considered to be “engineered" when at least one aspect of the polypeptide, e.g., its sequence, has been manipulated by the hand of man to differ from the aspect as it exists in nature. As is common practice and is understood by those in the art, progeny of an engineered cell are typically still referred to as “engineered" even though the actual manipulation was performed on a prior entity.

[0185] As used herein, the terms "treat,” "treatment," "treating,” or “amelioration” refer to therapeutic treatments, wherein the object is to reverse, alleviate, ameliorate, inhibit, slow down or stop the progression or severity of a condition associated with a disease or disorder, e.g. FPIAP and / or FPIES. The term “treating" includes reducing or alleviating at least one adverse effect or symptom of a condition, disease or disorder associated with a FPIAP and / or FPIES. Treatment is generally “effective" if one or more symptoms or clinical markers are reduced. Alternatively, treatment is “effective" if the progression of a disease is reduced or halted. That is, “treatment" includes not just the improvement of symptoms or markers, but also a cessation of, or at least slowing of, progress or worsening of symptoms compared to what would be expected in the absence of treatment. Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, remission (whether partial or total), and / or decreased mortality, whether detectable or undetectable. The term "treatment" of a disease also includes providing relief from the symptoms or side-effects of the disease (including palliative treatment). 33  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT

[0186] As used herein, the term “pharmaceutical composition” refers to the active agent in combination with a pharmaceutically acceptable carrier e.g. a carrier commonly used in the pharmaceutical industry. The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. In some embodiments of any of the aspects, a pharmaceutically acceptable carrier can be a carrier other than water. In some embodiments of any of the aspects, a pharmaceutically acceptable carrier can be a cream, emulsion, gel, liposome, nanoparticle, and / or ointment. In some embodiments of any of the aspects, a pharmaceutically acceptable carrier can be an artificial or engineered carrier, e.g., a carrier that the active ingredient would not be found to occur in or within nature.

[0187] As used herein, the term "administering," refers to the placement of a compound as disclosed herein into a subject by a method or route which results in at least partial delivery of the agent at a desired site. Pharmaceutical compositions comprising the compounds disclosed herein can be administered by any appropriate route which results in an effective treatment in the subject. In some embodiments, administration comprises physical human activity, e.g., an injection, act of ingestion, an act of application, and / or manipulation of a delivery device or machine. Such activity can be performed, e.g., by a medical professional and / or the subject being treated.

[0188] The term “effective amount" as used herein refers to the amount of medicament, composition, or formulation described herein (e.g., comprising B. infantis) needed to alleviate at least one or more symptom of the disease or disorder, and relates to a sufficient amount of pharmacological composition to provide the desired effect. The term "therapeutically effective amount" therefore refers to an amount of medicament, composition, or formulation described herein that is sufficient to provide a particular anti-FPIAP or anti-FPIES effect, anti-GERD, anti-hematochezia, anti-food allergy effect when administered to a typical subject. An effective amount as used herein, in various contexts, would also include an amount sufficient to delay the development of a symptom of the disease, alter the course of a symptom disease (for example but not limited to, slowing the progression of a symptom of the disease), or reverse a symptom of the disease. Thus, it is not generally practicable to specify an exact “effective amount". However, for any given case, an appropriate “effective amount" can be determined by one of ordinary skill in the art using only routine experimentation.

[0189] Effective amounts, toxicity, and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the ED50 (the dose therapeutically effective in 50% of the population). The dosage can vary depending upon the dosage form employed and the route of administration utilized. A therapeutically effective dose can be estimated initially from cell culture assays. The effects of any particular dosage can be monitored by a suitable bioassay, e.g., assay for microbiome composition, metagenomics, biomarkers 34  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT of chronic gut inflammation, among others. The dosage can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment.

[0190] The term “statistically significant" or “significantly" refers to statistical significance and generally means a two standard deviation (2SD) or greater difference.

[0191] Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.” The term “about” when used in connection with percentages can mean ±1%.

[0192] As used herein, the term “comprising” means that other elements can also be present in addition to the defined elements presented. The use of “comprising” indicates inclusion rather than limitation.

[0193] The term "consisting of" refers to compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment.

[0194] As used herein the term "consisting essentially of" refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the invention.

[0195] The singular terms "a," "an," and "the" include plural referents unless context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, suitable methods and materials are described below. The abbreviation, "e.g." is derived from the Latin exempli gratia, and is used herein to indicate a non-limiting example. Thus, the abbreviation "e.g." is synonymous with the term "for example."

[0196] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member can be referred to and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group can be included in, or deleted from, a group for reasons of convenience and / or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.

[0197] Unless otherwise defined herein, scientific and technical terms used in connection with the present application shall have the meanings that are commonly understood by those of ordinary skill in the art to which this disclosure belongs. It should be understood that this invention is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such can vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is defined solely by the claims. Definitions of common terms in cell biology, immunology, and molecular biology can be found in 35  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT The Merck Manual of Diagnosis and Therapy, 20th Edition, published by Merck Sharp & Dohme Corp., 2018 (ISBN 0911910190, 978-0911910421); Robert S. Porter et al. (eds.), The Encyclopedia of Molecular Cell Biology and Molecular Medicine, published by Blackwell Science Ltd., 1999-2012 (ISBN 9783527600908); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8); Immunology by Werner Luttmann, published by Elsevier, 2006; Janeway's Immunobiology, Kenneth Murphy, Allan Mowat, Casey Weaver (eds.), W. W. Norton & Company, 2016 (ISBN 0815345054, 978-0815345053); Lewin's Genes XI, published by Jones & Bartlett Publishers, 2014 (ISBN- 1449659055); Michael Richard Green and Joseph Sambrook, Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA (2012) (ISBN 1936113414); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (2012) (ISBN 044460149X); Laboratory Methods in Enzymology: DNA, Jon Lorsch (ed.) Elsevier, 2013 (ISBN 0124199542); Current Protocols in Molecular Biology (CPMB), Frederick M. Ausubel (ed.), John Wiley and Sons, 2014 (ISBN 047150338X, 9780471503385), Current Protocols in Protein Science (CPPS), John E. Coligan (ed.), John Wiley and Sons, Inc., 2005; and Current Protocols in Immunology (CPI) (John E. Coligan, ADA M Kruisbeek, David H Margulies, Ethan M Shevach, Warren Strobe, (eds.) John Wiley and Sons, Inc., 2003 (ISBN 0471142735, 9780471142737), the contents of which are all incorporated by reference herein in their entireties.

[0198] Other terms are defined herein within the description of the various aspects of the disclosure.

[0199] All patents and other publications; including literature references, issued patents, published patent applications, and co-pending patent applications; cited throughout this application are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that might be used in connection with the technology described herein. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents.

[0200] The description of embodiments of the disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. While specific embodiments of, and examples for, the disclosure are described herein for illustrative purposes, various equivalent modifications are possible within the scope of the disclosure, as those skilled in the relevant art will recognize. For example, while method steps or functions are presented in a given order, alternative embodiments can perform functions in a different order, or functions can be performed substantially concurrently. The teachings of the disclosure provided herein can be applied to other procedures or methods as 36  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT appropriate. The various embodiments described herein can be combined to provide further embodiments. Aspects of the disclosure can be modified, if necessary, to employ the compositions, functions and concepts of the above references and application to provide yet further embodiments of the disclosure. These and other changes can be made to the disclosure in light of the detailed description. All such modifications are intended to be included within the scope of the appended claims.

[0201] Specific elements of any of the foregoing embodiments can be combined or substituted for elements in other embodiments. Furthermore, while advantages associated with certain embodiments of the disclosure have been described in the context of these embodiments, other embodiments can also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the disclosure.

[0202] Some embodiments of the technology described herein can be defined according to any of the following numbered paragraphs: 1. A method of treating, preventing, or reducing the severity of symptoms of bloody stool in an infant patient in need thereof, the method comprising administering an effective amount of a medicament comprising one or more Bifidobacterium species. 2. The method of paragraph 1, wherein the Bifidobacterium species is selected from the group consisting of: Bifidobacterium breve, Bifidobacterium longum subsp longum, Bifidobacterium longum subsp infantis, Bifidobacterium longum subsp suis, Bifidobacterium pseudolongum, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Bifidobacterium catenulatum, Bifidobacterium bifidum, and Bifidobacterium dentium. 3. The method of paragraph 2, wherein the Bifidobacterium species is B. longum subspecies infantis. 4. The method of paragraph 3, wherein the Bifidobacterium comprises a functional H5 gene cluster that transports and metabolizes lacto-N-biose HMO derivates present in human milk. 5. The method of paragraph 4, where the functional H5 gene cluster comprises genes comprising greater than 90% sequence identity to the nucleic acid sequences of Blon_2171, Blon_2172, Blon_2173, Blon_2174, Blon_2175, Blon_2176, and / or Blon_2177. 6. The method of paragraph 5, wherein the functional H5 gene cluster is capable of expressing Blon_2171, Blon_2172, Blon_2173, Blon_2174, Blon_2175, Blon_2176, and Blon_2177. 7. The method of paragraph 6, wherein function of the Bifidobacterium is assessed by expression and activity of Blon_2176 in a reconstituted dried Bifidobacterium species or strain to transport and metabolize lacto-N-biose HMO derivatives present in human milk. 8. The method of paragraph 2, wherein the Bifidobacterium species expresses genes with at least 75% sequence identity to at least 9 of the genes selected from the group consisting of: Blon 2334- 2336, BLON 0243-0248, and Blon 0423-0428. 37  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT . The method of any one of paragraphs 3-8, wherein the Bifidobacterium species is B. infantis strain EVC001 (ATCC Accession No. PTA-125180) or ATCC strain 15697. 0. The method of any one of paragraphs 1-9, wherein the Bifidobacterium is activated. 1. The method of any one of paragraphs 1-10, wherein the infant patient receives 101to 1013cfu of the Bifidobacterium per day. 2. The method of any one of paragraphs 11, wherein, the infant patient receives at least 10 million – 100 million CFU of the Bifidobacterium per day. 3. The method of paragraph 11, wherein in the infant patient receives at least 100 million to at least 1 Billion CFU of the Bifidobacterium per day 4. The method of paragraph 11, wherein the infant patient receives at least 1 billion to at least 8 billion CFU of the Bifidobacterium per day. 5. The method of any one of paragraphs 11-14, wherein the Bifidobacterium is provided in a unit dose of 101to 1013cfu per dose. 6. The method of paragraph 15, wherein the unit dose is given 1-12 times per day to reach the total daily intake. 7. The method of any one of paragraphs 1-16, wherein the Bifidobacterium is in combination with a cryoprotectant. 8. The method of paragraph 17, wherein the cryoprotectant is selected from the group consisting of: sucrose, trehalose, maltodextrin, inulin, pea protein, milk fat globule membrane, glycomacropeptide (GMP), LNT, and LNnT, and combinations thereof. 9. The method of paragraph 17 or 18 wherein the cryoprotectant and Bifidobacterium mixture are frozen as a liquid product or dried (freeze-dried or spray-dried). 0. The method of any one of paragraphs 1-19, wherein the Bifidobacterium is in combination with an excipient selected from the group consisting of: lactose, MCT oil, MFGM, maltodextrin, LNT, LNnT, 2’FL, 3FL, infant formula, an exempt infant formula, human milk fortifier, and human milk product, and combinations thereof. 1. The method of any one of paragraphs 1-20, further comprising a second component selected from an HMO, a vitamin, and / or a source of DHA or other bacterial species. 2. The method of paragraph 21, further comprising a third component selected from an HMO, a vitamin, and / or a source of DHA. 3. The method of paragraph 22, further comprising a fourth component selected from an HMO, a vitamin, and / or a source of DHA. 4. The method of any one of paragraphs 21-23, wherein: (a) the HMO is selected from one of more of the group consisting of: lacto-N-biose (LNB), N-acetyl lactosamine, lacto-N-triose, lacto-N-tetraose (LNT), lacto-N- neotetraose (LNnT), fucosyllactose (FL), lacto-N-fucopentaose (LNFP), lactodifucotetraose, (LDFT) sialyllactose (SL), disialyllacto-N-tetraose (DSLNT), 2'- 38  895-6357-5489.5Attorney Docket No: 096910-000100WOPT fucosyllactose (2FL), 3’-sialyllactosamine (3SLN), 3'-fucosyllactose (3FL), 3'-sialyl- 3-fucosyllactose(3S3FL), 3'-sialyllactose (3SL), 6'-sialyllactosamine (6SLN), 6'- sialyllactose (6SL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFPI), lacto- N-fucopentaose II (LNFPII), lacto-N-fucopentaose III (LNFPIII), lacto-N- fucopentaose V (LNFPV), and sialyllacto-N-tetraose (SLNT), and their derivatives, and combinations thereof; (b) the HMO is LNT at 0.5 -10g / d; (c) the vitamin is selected from the group consisting of: Vitamin A (retinol, carotenoids), Vitamin B (thiamine, riboflavin, niacin, niacinamide, pantothenic acid, pyridoxine, pyradoxamin, pyridoxal, biotin, folic acid, folate, folic acid, cyanocobalamin, hydroxocobalamin, methylcarbylamine), Vitamin C (ascorbic acid), Vitamin D (cholecalciferol, ergocalciferol), Vitamin E (tocopherols, tocotrienols), and Vitamin K (phylloquinone, menaquinone); (d) the vitamin is Vitamin D at 5-25 ug / d; (e) the DHA source is selected from the group consisting of: fish oil, algal oil, and oil from recombinant plants or microorganisms; (f) the DHA is a triglyceride delivering 1-50 mg DHA / d; and / or (g) the other bacterial species are selected from Akkermansia and Lactobacillus, optionally wherein the Akkermansia species is selected from the group consisting of: Akkermansia muciniphila and Akkermansia glycaniphila; optionally wherein the Lactobacillus species is selected from the group consisting of: Lactobacillus crispatus, Lactobacillus johnsonii, Lacticaseibacillus rhamnosus, Limosilactobacillus reuteri, and Lacticaseibacillus paracasei. 5. The method of any one of paragraphs 1-24, wherein: (a) the medicament is formulated as a powder; (b) the medicament is formulated as a gel, butter or paste; (c) the medicament is formulated as a liquid suspension; (d) the medicament is formulated as an oil; (e) the medicament is formulated as a foam; (f) the medicament is formulated to be delivered orally; and / or (g) the medicament is formulated to be delivered as a suppository. 6. The method of any one of paragraphs 1-25, wherein the medicament comprises a food, a food for special dietary use (FSDU), a medical food, a dietary supplement, or a live bacterial therapeutic (LBT). 7. The method of paragraph 26, wherein the medicament is manufactured and packaged at a pharmaceutical grade for use as a live bacterial therapeutic. 39  895-6357-5489.5Attorney Docket No: 096910-000100WOPT 8. The method of paragraph 26, wherein the FSDU, medical food and / or dietary supplement is in combination with a preterm infant formula, term infant formula, soy-based formula, follow-on formula, bovine based human milk fortifier, human based human milk fortifier, expressed human milk, expressed pasteurized donor milk, enriched human whey permeate (dried or liquid), or purified human milk oligosaccharides from natural or synthetic sources. 9. The method of paragraph 28, wherein the medicament is added to the FSDU, medical food and / or dietary supplement at time of manufacture or at the time of consumption. 0. The method of paragraph 26, wherein the unit size of the FSDU, medical food and / or dietary supplement is a single serving or dose. 1. The method of any one of paragraphs 1-26, wherein the medicament is formulated for consumption by the infant patient. 2. The method of any one of paragraphs 26-31, wherein the medicament prevents, treats, reduces, or resolves hematochezia and / or anemia in the infant patient. 3. The method of any one of paragraphs 26-31, wherein the medicament treats, reduces, or resolves symptoms of FPIAP and FPIES in the infant patient. 4. The method of any one of paragraphs 26-31, wherein the medicament prevents FPIAP or FPIES in the infant patient. 5. The method of any one of paragraphs 31-34, wherein the infant patient is a term infant. 6. The method of paragraph 32, wherein the infant patient is a preterm infant. 7. The method of paragraph 35, wherein the term infant’s age is 0-3 months, 0-6 months, 6-12 months, 21-24 months, or 0-24 months. 8. The method of paragraph 36, wherein the preterm infant is extremely low birth weight (ELBW), very low birth weight (VLBW), low birth weight (LBW) and / or less than 33 weeks gestational age at birth or less than 31 weeks. 9. The method of any one of paragraphs 1-38, wherein the infant patient is selected from an infant with risk factors for bloody stool selected from the group consisting of: prematurity, family history of bloody stool or food allergy, past history of atopic dermatitis, gut dysbiosis, C- section, antibiotic use, and cow’s milk protein sensitivity. 0. The method of any one of paragraphs 1-39, wherein the patient or patient population is selected based on onset of symptoms selected from the group consisting of: bloody stools, IgE antibodies, autoantibodies, excessive crying, low anthropometric scores, poor cognitive scores, high level of enteric or systemic inflammation (e.g., > 200ug / mg fecal calprotectin), feeding difficulty, wheezing, vomiting, and reflux (GERD). 1. A method of treating, preventing, or reducing the severity of FPIAP, the method comprising administering an effective amount of a medicament comprising one or more Bifidobacterium species to an infant subject in need thereof. 40  895-6357-5489.5Attorney Docket No: 096910-000100WOPT 2. The method of paragraph 41, wherein the medicament is administered in a background of or in combination with cow’s milk protein. 3. The method of paragraph 42, wherein the Cow’s milk protein is from addition of bovine based infant formula, transfer through breast milk (e.g., increased dairy consumption by a breast-feeding mother), yogurt, or cheese to the infant diet. 4. A method of treating hematochezia in an infant subject, the method comprising administering an effective amount of a medicament comprising one or more Bifidobacterium species to an infant subject in need thereof. 5. The method of paragraph 44, wherein the hematochezia is associated with FPIAP pr FPIES.6. The method of paragraph 44 or 45, wherein: (a) the medicament is provided within 1 hour, 2 hours, or up to 5 days after the day of diagnosis; (b) the medicament is provided on a daily basis for at least 1-100 days and / or until hematochezia or bloody stool is resolved; and / or (c) the medicament is provided to the subject one or more times / day but not exceeding the total daily intake. 7. The method of any one of paragraphs 41-46, wherein the treatment is initiated within the first year of life. 8. The method of any one of paragraphs 41-47, wherein the treatment is provided to one or both of a mother-infant pair in conjunction with breast-feeding. 9. The method of paragraph 48, wherein breastfeeding duration is increased. 0. The method of paragraph 48 or 49, wherein the mother is in the 3rdor 4thtrimester, or wherein the mother is breast-feeding. 1. A method of treating FPIAP or FPIES comprising: (a) identifying an infant patient with FPIAP by any one of the following symptoms: (i) elevated stool inflammatory markers; (ii) elevated eotaxin levels; (iii) bloody stool; (iv) stool B. infantis comprising less than 5% of the infant gut microbiome; (v) stool Enterobacteriaceae exceeding 20% of the infant gut microbiome; (vi) excess stool mucus; and / or (vii) feeding difficulty, wheezing, vomiting and / or reflux (GERD); (b) providing the patient with an effective amount of a medicament comprising one or more Bifidobacterium species according to a daily dose; and (c) monitoring the symptoms of the patient until any or all of the symptoms are resolved. 2. A method of treating hematochezia comprising: identifying an infant patient with hematochezia using a stool occult test; 41  895-6357-5489.5Attorney Docket No: 096910-000100WOPT providing the patient with an effective amount of a medicament comprising one or more Bifidobacterium species according to a daily total intake; and monitoring the patient until the hematochezia is resolved. 3. A method of reducing the risk of IgE-based food allergies and / or asthma by treating patients with FPIAP or FPIES with an effective amount of a medicament comprising one or more Bifidobacterium species. 4. The method of 53, wherein the food allergy is elevated IgE for egg, milk, or peanut. 5. The method of any one of paragraphs 41-54, wherein treatment efficacy is measured by one or more of: decreased gut pH, a change in metagenomic sequencing, reduction or enrichment of at least one metabolite, and / or change in inflammatory profile. 6. The method of paragraph 55, wherein the at least one metabolite is selected from the group consisting of: adenine, N-acetylgluco-saminyl-asparagine, sphingomyelin, PAHSA, gamma- glutamylmethionine, glutamate gamma-methyl ester, lactate, sedoheptulose, indolelactate, N- acetylneuraminate (Neu5Ac), gulonate, serotonin, OH-PLA, indole, phenyllactate (PLA), 4- hydroxy-phenyllactate (4-OH-PLA), and nicotinamide riboside. 7. The method of paragraph 55, wherein the change in metagenomic sequencing comprises: an enrichment of HMO metabolizing genes and / or aromatic lactic acid pathways, and / or a reduction of antibiotic resistance genes and / or formate biosynthesis pathways. 8. The method of paragraph 55, wherein the change in metagenomic sequencing comprises B. infantis comprising greater than 30% of the total gut microbiome and Enterobacteriaceae comprising less than 20% of the total gut microbiome. 9. The method of paragraph 55, wherein the inflammatory profile comprises levels of one or more inflammatory cytokines selected from the group consisting of: IL-1α, MIP1a, GM-CSF, TARC, MIP-1B, IL-16, IL-2, MCP-1, MCP-4, VEGF, IFN-β, IL-13, MIP-3a, IL-17A, IL-31, IL-21, IL- 33, and eotaxin. 0. The method of paragraph 59, wherein fecal IL-1α, IFN-β, and Galectin-1 are increased, and fecal GM-CSF, TARC, MIP-1B, MCP-1, MCP-4, VEGF, IL-13, MIP-3a, IL-17A, IL-31, IL-21, IL-33, and eotaxin are decreased in comparison to pretreatment samples and / or control subject samples. 1. A method of treating, preventing, or reducing the severity of FPIAP or FPIES in an infant in need thereof, the method comprising administering a composition comprising a therapeutically effective amount of a Bifidobacterium to the infant, whereby FPIAP or FPIES is treated, prevented, or severity reduced. 2. The method of paragraph 61, wherein the method further comprises the step of monitoring the patient until any or all of the symptoms of FPIAP or FPIES are resolved. 3. The method of paragraph 61, wherein the method further comprises a step, before the administering step, of receiving diagnostic results indicating that the subject has FPIAP or FPIES. 42  895-6357-5489.5Attorney Docket No: 096910-000100WOPT 4. The method of paragraph 61, wherein the method further comprises a step, before the administering step, of performing a diagnostic test for FPIAP or FPIES. 5. The method of paragraph 64, wherein diagnosis is based on one or more markers selected from the group consisting of: elevated stool inflammatory markers, stool B. infantis comprising less than 5% of the infant gut microbiome, stool Enterobacteriaceae exceeding 20% of the infant gut microbiome, and excess stool mucus. 6. The method of paragraph 65, wherein one or more stool inflammatory markers are selected from the group consisting of: IL-1α, MIP1a, GM-CSF, TARC, MIP-1B, IL-16, IL-2, MCP-1, MCP-4, VEGF, IFN-β, IL-13, MIP-3a, IL-17A, IL-31, IL-21, IL-33, and eotaxin. 7. A method of treating, preventing, or reducing the severity of hematochezia, the method comprising administering to a subject diagnosed with hematochezia, a composition comprising a Bifidobacterium in an amount effective to treat, prevent, or reduce the severity of hematochezia, whereby the hematochezia is treated, prevented, or the severity reduced. 8. The method of paragraph 67, wherein the method further comprises identifying a patient at risk for hematochezia, using risk factors selected from the group consisting of: prematurity, low gestational age, low birth weight, increased time on Total Parenteral Nutrition (TPN), increased time to full feeds, increased nil per os (NPO), elevated stool inflammatory markers, stool B. infantis comprising 5% of the total gut microbiome, and Enterobacteriaceae comprising greater than 45%. 9. The method of paragraph 67, wherein the hematochezia is determined to be effectively treated when there is a decrease in time to full feeds, decrease in nil per os (NPO), and decrease in time on TPN. 0. The method of paragraph 67, wherein the hematochezia is determined to be effectively treated when B. infantis comprises over 30% of the total gut microbiome and Enterobacteriaceae comprises less than 30%. 1. The method of any one of paragraphs 67-70, further comprising a step, before the administering step, of receiving diagnostic results indicating that the subject has hematochezia. 2. The method of any one of paragraphs 67-71, where in the method reduces the incidence of spontaneous intestinal perforation, late onset sepsis, anemia, and / or necrotizing colitis. 3. The method of any one of paragraphs 67-72, further comprising a step, before the administering step, of performing a diagnostic test for hematochezia. 4. A method for reducing the risk of IgE-based food allergy or asthma in an infant with FPIAP or FPIES, the method comprising administering a composition comprising a therapeutically effective amount of a Bifidobacterium to the infant, whereby the infant’s risk of IgE-based food allergy is reduced relative to an infant with FPIAP or FPIES not administered the composition. 5. The method of paragraph 74, wherein the Bifidobacterium is in a medicament. 43  895-6357-5489.5Attorney Docket No: 096910-000100WOPT 76. A method of treating, preventing, or reducing the severity of FPIAP or FPIES, the method comprising administering a composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis EVC001, which is effective when reconstituted in vivo. 77. The method of paragraph 76, wherein the B. infantis is reconstituted at the time of consumption or in vivo. 78. A method of treating, preventing, or reducing the severity of hematochezia, the method comprising administering a composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis, which is effective when reconstituted in vivo. 79. The method of paragraph 78, wherein the B. infantis is reconstituted at time of consumption or in vivo. 80. A method of reducing the risk of IgE-based food allergy or asthma in an infant with FPIAP or FPIES, the method comprising administering a composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis, which is effective when reconstituted in vivo. 81. The method of paragraph 80, wherein the dried B. infantis is reconstituted at time of consumption or in vivo. 82. A composition comprising one or more Bifidobacterium species for use in an infant patient exhibiting symptoms of bloody stool. 83. A composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis EVC001 for use in the treatment of FPIAP or FPIES, which is effective when reconstituted in vivo. 84. A composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis for use in treating hematochezia, which is effective when reconstituted in vivo. 85. A composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis for use in reducing the risk of IgE-based food allergy or asthma in an infant with FPIAP or FPIES, which is effective when reconstituted in vivo.

[0203] Some embodiments of the technology described herein can be defined according to any of the following numbered paragraphs: 1. A medicament comprising one or more Bifidobacterium species for use in an infant patient exhibiting symptoms of bloody stool. 2. The medicament of paragraph 1, wherein the Bifidobacterium species is selected from the group consisting of: Bifidobacterium breve, Bifidobacterium longum subsp longum, Bifidobacterium longum subsp infantis, Bifidobacterium longum subsp suis, Bifidobacterium pseudolongum, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Bifidobacterium catenulatum, Bifidobacterium bifidum, and Bifidobacterium dentium. 44  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT . The medicament of paragraph 2, wherein the Bifidobacterium species is B. longum subspecies infantis. . The medicament of paragraph 3, wherein the Bifidobacterium comprises a functional H5 gene cluster that transports and metabolizes lacto-N-biose HMO derivates present in human milk.. The medicament of paragraph 4, where the functional H5 gene cluster comprises genes comprising greater than 90% sequence identity to the nucleic acid sequences of Blon_2171, Blon_2172, Blon_2173, Blon_2174, Blon_2175, Blon_2176, and / or Blon_2177. . The medicament of paragraph 5, wherein the functional H5 gene cluster is capable of expressing Blon_2171, Blon_2172, Blon_2173, Blon_2174, Blon_2175, Blon_2176, and Blon_2177.. The medicament of paragraph 6, wherein function of the Bifidobacterium is assessed by expression and activity of Blon_2176 in a reconstituted dried Bifidobacterium species or strain to transport and metabolize lacto-N-biose HMO derivatives present in human milk. . The medicament of paragraph 2, wherein the Bifidobacterium species expresses genes with at least 75% sequence identity to at least 9 of the genes selected from the group consisting of: Blon 2334-2336, BLON 0243-0248, and Blon 0423-0428. . The medicament of paragraph 3-8, wherein the Bifidobacterium species is B. infantis strain EVC001 (ATCC Accession No. PTA-125180) or ATCC strain 15697. 0. The medicament of paragraph 1-9, wherein the Bifidobacterium is activated. 1. The medicament of paragraph 1-10, wherein the infant patient receives 101to 1013cfu of the Bifidobacterium per day. 2. The medicament of paragraph 11, wherein, the infant patient receives at least 10 million – 100 million CFU of the Bifidobacterium per day. 3. The medicament of paragraph 11, wherein in the infant patient receives at least 100 million to at least 1 Billion CFU of the Bifidobacterium per day 4. The medicament of paragraph 11, wherein the infant patient receives at least 1 billion to at least 8 billion CFU of the Bifidobacterium per day. 5. The medicament of any paragraph 11-14, wherein the Bifidobacterium is provided in a unit dose of 101to 1013cfu per dose. 6. The medicament of paragraph 15, wherein the unit dose is given 1-12 times per day to reach the total daily intake. 7. The medicament of paragraph 1-16, wherein the Bifidobacterium is in combination with a cryoprotectant. 8. The medicament of paragraph 17, wherein the cryoprotectant is selected from the group consisting of: sucrose, trehalose, maltodextrin, inulin, pea protein, milk fat globule membrane, glycomacropeptide (GMP), LNT, and LNnT, and combinations thereof. 9. The medicament of paragraph 17-18 wherein the cryoprotectant and Bifidobacterium mixture are frozen as a liquid product or dried (freeze-dried or spray-dried). 45  895-6357-5489.5Attorney Docket No: 096910-000100WOPT 0. A medicament of paragraph 1-19, wherein the Bifidobacterium is in combination with an excipient selected from the group consisting of: lactose, MCT oil, MFGM, maltodextrin, LNT, LNnT, 2’FL, 3FL, infant formula, an exempt infant formula, human milk fortifier, and human milk product, and combinations thereof. 1. The medicament of paragraph 1-20, further comprising a second component selected from an HMO, a vitamin, and / or a source of DHA or other bacterial species. 2. The medicament of paragraph 21, further comprising a third component selected from an HMO, a vitamin, and / or a source of DHA. 3. The medicament of paragraph 22, further comprising a fourth component selected from an HMO, a vitamin, and / or a source of DHA. 4. The medicament of any one of paragraphs 21-23, wherein: (a) the HMO is selected from one of more of the group consisting of: lacto-N-biose (LNB), N-acetyl lactosamine, lacto-N-triose, lacto-N-tetraose (LNT), lacto-N- neotetraose (LNnT), fucosyllactose (FL), lacto-N-fucopentaose (LNFP), lactodifucotetraose, (LDFT) sialyllactose (SL), disialyllacto-N-tetraose (DSLNT), 2'- fucosyllactose (2FL), 3’-sialyllactosamine (3SLN), 3'-fucosyllactose (3FL), 3'-sialyl- 3-fucosyllactose(3S3FL), 3'-sialyllactose (3SL), 6'-sialyllactosamine (6SLN), 6'- sialyllactose (6SL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFPI), lacto- N-fucopentaose II (LNFPII), lacto-N-fucopentaose III (LNFPIII), lacto-N- fucopentaose V (LNFPV), and sialyllacto-N-tetraose (SLNT), and their derivatives, and combinations thereof; (b) the HMO is LNT at 0.5 -10g / d; (c) the vitamin is selected from the group consisting of: Vitamin A (retinol, carotenoids), Vitamin B (thiamine, riboflavin, niacin, niacinamide, pantothenic acid, pyridoxine, pyradoxamin, pyridoxal, biotin, folic acid, folate, folic acid, cyanocobalamin, hydroxocobalamin, methylcarbylamine), Vitamin C (ascorbic acid), Vitamin D (cholecalciferol, ergocalciferol), Vitamin E (tocopherols, tocotrienols), and Vitamin K (phylloquinone, menaquinone); (d) the vitamin is Vitamin D at 5-25 ug / d; (e) the DHA source is selected from the group consisting of: fish oil, algal oil, and oil from recombinant plants or microorganisms; (f) the DHA is a triglyceride delivering 1-50 mg DHA / d; and / or (g) the other bacterial species are selected from Akkermansia and Lactobacillus, optionally wherein the Akkermansia species is selected from the group consisting of: Akkermansia muciniphila and Akkermansia glycaniphila; optionally wherein the Lactobacillus species is selected from the group consisting of: Lactobacillus 46  895-6357-5489.5Attorney Docket No: 096910-000100WOPT crispatus, Lactobacillus johnsonii, Lacticaseibacillus rhamnosus, Limosilactobacillus reuteri, and Lacticaseibacillus paracasei. 5. The medicament of any one of the preceding paragraphs, wherein: (a) the medicament is formulated as a powder; (b) the medicament is formulated as a gel, butter or paste; (c) the medicament is formulated as a liquid suspension; (d) the medicament is formulated as an oil; (e) the medicament is formulated as a foam; (f) the medicament is formulated to be delivered orally; and / or (g) the medicament is formulated to be delivered as a suppository. 6. The medicament of any one of paragraphs 1-25, wherein the medicament comprises a food, a food for special dietary use (FSDU), a medical food, a dietary supplement, or a live bacterial therapeutic (LBT). 7. The medicament of paragraph 26, wherein the medicament is manufactured and packaged at a pharmaceutical grade for use as a live bacterial therapeutic. 8. The medicament of paragraph 26, wherein the FSDU, medical food and / or dietary supplement is in combination with a preterm infant formula, term infant formula, soy-based formula, follow-on formula, bovine based human milk fortifier, human based human milk fortifier, expressed human milk, expressed pasteurized donor milk, enriched human whey permeate (dried or liquid), or purified human milk oligosaccharides from natural or synthetic sources. 9. The medicament of paragraph 28, wherein the medicament is added to the FSDU, medical food and / or dietary supplement at time of manufacture or at the time of consumption. 0. The medicament of paragraph 26, wherein the unit size of the FSDU, medical food and / or dietary supplement is a single serving or dose. 1. The medicament of any one of paragraphs 1-26, wherein the medicament is formulated for consumption by the infant patient. 2. The medicament of paragraph 26-31, wherein the medicament prevents, treats, reduces, or resolves hematochezia and / or anemia in the infant patient. 3. The medicament of paragraph 26-31, wherein the medicament treats, reduces, or resolves symptoms of FPIAP and FPIES in the infant patient. 4. The medicament of paragraph 26-31, wherein the medicament prevents FPIAP or FPIES in the infant patient. 5. The medicament of any one of paragraphs 31-34, wherein the infant patient is a term infant.6. The medicament of paragraph 32, wherein the infant patient is a preterm infant. 7. The medicament of paragraph 35, wherein the term infant’s age is 0-3 months, 0-6 months, 6-12 months, 21-24 months, or 0-24 months. 47  895-6357-5489.5Attorney Docket No: 096910-000100WOPT 8. The medicament of paragraph 36, wherein the preterm infant is extremely low birth weight (ELBW), very low birth weight (VLBW), low birth weight (LBW) and / or less than 33 weeks gestational age at birth or less than 31 weeks. 9. The medicament of any one of the preceding paragraphs, wherein the infant patient is selected from an infant with risk factors for bloody stool selected from the group consisting of: prematurity, family history of bloody stool or food allergy, past history of atopic dermatitis, gut dysbiosis, C- section, antibiotic use, and cow’s milk protein sensitivity. 0. The medicament of any one of the preceding paragraphs, wherein the patient or patient population is selected based on onset of symptoms selected from the group consisting of: bloody stools, IgE antibodies, autoantibodies, excessive crying, low anthropometric scores, poor cognitive scores, high level of enteric or systemic inflammation (e.g., > 200ug / mg fecal calprotectin), wheezing, vomiting, and reflux (GERD). 1. A method of treating, preventing or reducing the severity of FPIAP, the method comprising administering a medicament of any one of paragraphs 1-40 to an infant subject in need thereof. 2. The method of paragraph 41, wherein the medicament from any one of paragraphs 1-40 is administered in a background of or in combination with cow’s milk protein. 3. The method of paragraph 42, wherein the Cow’s milk protein is from addition of bovine based infant formula, transfer through breast milk (e.g., increased dairy consumption by a breast-feeding mother), yogurt, or cheese to the infant diet. 4. A method of treating hematochezia in an infant subject, the method comprising administering a medicament of any one of paragraphs 1-40 to an infant subject in need thereof. 5. The method of paragraph 44, wherein the hematochezia is associated with FPIAP pr FPIES.6. The method of paragraph 44 or 45, wherein: (a) the medicament is provided within 1 hour, 2 hours, or up to 5 days after the day of diagnosis; (b) the medicament is provided on a daily basis for at least 1-100 days and / or until hematochezia or bloody stool is resolved; and / or (c) the medicament is provided to the subject one or more times / day but not exceeding the total daily intake. 7. The method of any one of paragraphs 41-46, wherein the treatment is initiated within the first year of life. 8. The method of any one of the paragraphs 41-47, wherein the treatment is provided to one or both of a mother-infant pair in conjunction with breast-feeding. 9. The method of paragraph 48, wherein breastfeeding duration is increased. 0. The method of paragraph 48 or 49, wherein the mother is in the 3rdor 4thtrimester, or wherein the mother is breast-feeding. 1. A method of treating FPIAP or FPIES comprising: 48  895-6357-5489.5Attorney Docket No: 096910-000100WOPT (a) identifying an infant patient with FPIAP by any one of the following symptoms: (i) elevated stool inflammatory markers; (ii) elevated eotaxin levels; (iii) bloody stool; (iv) stool B. infantis comprising less than 5% of the infant gut microbiome; (v) stool Enterobacteriaceae exceeding 20% of the infant gut microbiome; (vi) excess stool mucus; and / or (vii) wheezing, vomiting and / or reflux (GERD); (b) providing the patient with the medicament of any one of paragraphs 1-40 according to the daily dose; and (c) monitoring the symptoms of the patient until any or all of the symptoms are resolved. 2. A method of treating hematochezia comprising: identifying an infant patient with hematochezia using a stool occult test; providing the patient with the medicament of any one of paragraphs 1-40 according to the daily total intake; and monitoring the patient until the hematochezia is resolved. 3. A method of reducing the risk of IgE-based food allergies and / or asthma by treating patients with FPIAP or FPIES with the medicament of any one of paragraphs 1-40. 4. The method of 53, wherein the food allergy is elevated IgE for egg, milk, or peanut. 5. The method of any one of paragraphs 41-54, wherein treatment efficacy is measured by one or more of: decreased gut pH, a change in metagenomic sequencing, reduction or enrichment of at least one metabolite, and / or change in inflammatory profile. 6. The method of paragraph 55, wherein the at least one metabolite is selected from the group consisting of: adenine, N-acetylgluco-saminyl-asparagine, sphingomyelin, PAHSA, gamma- glutamylmethionine, glutamate gamma-methyl ester, lactate, sedoheptulose, indolelactate, N- acetylneuraminate (Neu5Ac), gulonate, serotonin, OH-PLA, indole, phenyllactate (PLA), 4- hydroxy-phenyllactate (4-OH-PLA), and nicotinamide riboside. 7. The method of paragraph 55, wherein the change in metagenomic sequencing comprises: an enrichment of HMO metabolizing genes and / or aromatic lactic acid pathways, and / or a reduction of antibiotic resistance genes and / or formate biosynthesis pathways. 8. The method of paragraph 55, wherein the change in metagenomic sequencing comprises B. infantis comprising greater than 30% of the total gut microbiome and Enterobacteriaceae comprising less than 20% of the total gut microbiome. 9. The method of paragraph 55, wherein the inflammatory profile comprises levels of one or more inflammatory cytokines selected from the group consisting of: IL-1α, MIP1a, GM-CSF, TARC, MIP-1B, IL-16, IL-2, MCP-1, MCP-4, VEGF, IFN-β, IL-13, MIP-3a, IL-17A, IL-31, IL-21, IL- 33, and eotaxin. 49  895-6357-5489.5Attorney Docket No: 096910-000100WOPT 0. The method of paragraph 59, wherein fecal IL-1α, IFN-β, and Galectin-1 are increased, and fecal GM-CSF, TARC, MIP-1B, MCP-1, MCP-4, VEGF, IL-13, MIP-3a, IL-17A, IL-31, IL-21, IL-33, and eotaxin are decreased in comparison to pretreatment samples and / or control subject samples. 1. A method of treating FPIAP or FPIES in an infant in need thereof, the method comprising administering a composition comprising a therapeutically effective amount of a Bifidobacterium to the infant, whereby FPIAP or FPIES is treated. 2. The method of paragraph 61, wherein the method further comprises the step of monitoring the patient until any or all of the symptoms of FPIAP or FPIES are resolved. 3. The method of paragraph 61, wherein the method further comprises a step, before the administering step, of receiving diagnostic results indicating that the subject has FPIAP or FPIES. 4. The method of paragraph 61, wherein the method further comprises a step, before the administering step, of performing a diagnostic test for FPIAP or FPIES. 5. The method of paragraph 64, wherein diagnosis is based on one or more markers selected from the group consisting of: elevated stool inflammatory markers, stool B. infantis comprising less than 5% of the infant gut microbiome, stool Enterobacteriaceae exceeding 20% of the infant gut microbiome, and excess stool mucus. 6. The method of paragraph 65, wherein one or more stool inflammatory markers are selected from the group consisting of: IL-1α, MIP1a, GM-CSF, TARC, MIP-1B, IL-16, IL-2, MCP-1, MCP-4, VEGF, IFN-β, IL-13, MIP-3a, IL-17A, IL-31, IL-21, IL-33, and eotaxin. 7. A method of treating hematochezia, the method comprising administering to a subject diagnosed with hematochezia, a composition comprising a Bifidobacterium in an amount effective to treat hematochezia, whereby the hematochezia is treated. 8. The method of paragraph 67, wherein the method further comprises identifying a patient at risk for hematochezia, using risk factors selected from the group consisting of: prematurity, low gestational age, low birth weight, increased time on Total Parenteral Nutrition (TPN), increased time to full feeds, increased nil per os (NPO), elevated stool inflammatory markers, stool B. infantis comprising 5% of the total gut microbiome, and Enterobacteriaceae comprising greater than 45%. 9. The method of paragraph 67, wherein the hematochezia is determined to be effectively treated when there is a decrease in time to full feeds, decrease in nil per os (NPO), and decrease in time on TPN. 0. The method of paragraph 67, wherein the hematochezia is determined to be effectively treated when B. infantis comprises over 30% of the total gut microbiome and Enterobacteriaceae comprises less than 30%. 1. The method of any one of paragraphs 67-70, further comprising a step, before the administering step, of receiving diagnostic results indicating that the subject has hematochezia. 50  895-6357-5489.5Attorney Docket No: 096910-000100WOPT 72. The method of any one of paragraphs 67-71, where in the method reduces the incidence of spontaneous intestinal perforation, late onset sepsis, anemia, and / or necrotizing colitis. 73. The method of any one of paragraphs 67-72, further comprising a step, before the administering step, of performing a diagnostic test for hematochezia. 74. A method for reducing the risk of IgE-based food allergy or asthma in an infant with FPIAP or FPIES, the method comprising administering a composition comprising a therapeutically effective amount of a Bifidobacterium to the infant, whereby the infant’s risk of IgE-based food allergy is reduced relative to an infant with FPIAP or FPIES not administered the composition. 75. The method of paragraph 74, wherein the Bifidobacterium is in a medicament of any one of paragraphs 1-40. 76. A composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis EVC001 for use in the treatment of FPIAP or FPIES, which is effective when reconstituted in vivo. 77. The composition for use of paragraph 76, wherein the B. infantis is reconstituted at the time of consumption or in vivo. 78. A composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis for use in treating hematochezia, which is effective when reconstituted in vivo. 79. The composition for use of paragraph 78, wherein the B. infantis is reconstituted at time of consumption or in vivo. 80. A composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis for use in reducing the risk of IgE-based food allergy or asthma in an infant with FPIAP or FPIES, which is effective when reconstituted in vivo. 81. The composition for use of paragraph 80, wherein the dried B. infantis is reconstituted at time of consumption or in vivo.

[0204] The technology described herein is further illustrated by the following examples which in no way should be construed as being further limiting. EXAMPLES EXAMPLE 1. Clinical trials for the treatment or prevention of FPIAP or hematochezia A. Treatment of FPIAP in term infants

[0205] Longitudinal pediatric cohort analysis has identified bacterial dysbiosis in the gut microbiomes of infants diagnosed with FPIAP (Martin, V. M. et al. Longitudinal disease-associated gut microbiome differences in infants with food protein-induced allergic proctocolitis. Microbiome 10, 154 (2022)). Further, the enrichment of Enterobacteriaceae has been 51  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT identified as marker of FPIAP within a cohort. Rates of FPIAP can be as high as 1%-20% in some regions of the US (Martin, V. M. et al. Prospective Assessment of Pediatrician-Diagnosed Food Protein–Induced Allergic Proctocolitis by Gross or Occult Blood. J Allergy Clin Immunol Pract 8, 1692-1699.e1 (2020)).

[0206] For this single-center, double-blinded, randomized, placebo-controlled trial, approximately 150 infants aged 1-60 days old with documented FPIAP will be enrolled. Subjects will be allocated 1:1 to two study arms; 1) a treatment group receiving a daily medicament, and 2) a control group receiving a daily placebo. FPIAP will be documented as either gross or microscopic blood in the stool, if no other cause can be identified. Blood in the stool will be assayed by either a) an immunoassay recognizing globin antigen, b) heme-porphyrin assay, or c) guaiac-based test on a stool card, the most widely used. Infants must be born with a gestational period of 37-42 weeks. Study product will provided daily from Day 1 to Day 14 with the study completing on Study Day 28. Samples will be collected throughout the study at applicable time points. As an example, stool swabs and stool samples will be collected at baseline, Day 1, Day 7, Day 14, Day 21, and Day 28. Hemoccult card stool smears (X, X) will be collected daily. In addition to biological sampling, questionnaires will be collected from caregivers to evaluate frequency, duration, and consistency of sleep, feeding, stooling, gross blood in stool, and fussiness. The primary endpoint will be time to resolution of FPIAP.

[0207] Table 8 Proposed Analysis Biological Sample ve rs H,B. Prevention of FPIAP in term infants

[0208] A treatment to prevent FPIAP, one of the earliest biomarkers for allergic disease, can be protective later in the infant’s life and, thus, should be explored as a disease prevention early in life (Cetinkaya, P. G., Ocak, M., Sahiner, U. M., Sekerel, B. E. & Soyer, O. Food protein–induced allergic proctocolitis can have distinct phenotypes. Ann Allergy Asthma Immunol 126, 75–82 (2021)). 52  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT

[0209] Prevention of FPIAP will be tested in a multi-center, double-blinded, randomized, placebo-controlled trial. Approximately 750 infants will be enrolled from 0 to 90 days of life who 1) have a family history of food allergies, and / or 2) older siblings have been diagnosed with FPIAP. Subjects will be randomly assigned 1:1 to the two study arms: 1) daily medicament, or 2) daily placebo. Subjects will receive the medicament or placebo from Study Day 1 to Study Day 90, with monitoring of subjects until 12 mos of age. Stool swabs, stool samples, and hemoccult stool cards will be collected monthly until the subject reaches 12 mos of age. The subject’s doctor and caregivers will monitor for gross blood in the stool. Proposed analysis will be consistent with those outlined for FPIAP treatment, above (see e.g., Table 8). The primary endpoint will be reduction in FPIAP incidence at 12 months of age. Additionally, food allergy for milk, egg, and peanut (IgE-mediated) will be evaluated in both groups at 12 months. C. Prevention of hematochezia and bloody stool in preterm population

[0210] Hematochezia or bloody stool in preterm infants (defined as less than < 336 / 7 weeks GA) is clinically characterized by gross blood and / or occult blood and can be used as a diagnostic. In some cases, blood loss can lead to anemia characterized by lethargy and poor feeding. It is expected that 15-20% of VLBW and >20% in ELBW infants will develop symptoms of bloody stool that adversely affect feeding effectiveness. Bloody stool contributes to feeding intolerance, which is a challenge in the Neonatal Intensive Care Unit (NICU) leading to increased cumulative NPO days for which there is currently no specific treatment. Current management includes holding feeds until gross blood disappears and can involve a short course of antibiotics and blood transfusions for low hematocrit.

[0211] For the prevention of hematochezia and anemia in a preterm population, a randomized, double-blind, placebo-controlled, two-arm, parallel-group study will be conducted with hospitalized preterm infants in the NICU. Each infant enrolled will be stratified by birth weight (1250-1500, 1001- 1250g, 750-1000g, or <750g) and will have corrected gestational age less than (or equal to) 31 weeks AND birth and will be enrolled at ≤ 7 days of life and considered viable. Infants will be randomized after maternal consenting and all screening procedures are completed. The study product will be single-serving doses of B. infantis (EVC001), containing a minimum of 8 billion colony forming units (CFU) of activated B. infantis EVC001 suspended in MCT oil, and matching placebo.

[0212] A single-serving dose of B. infantis (EVC001) suspended in MCT oil or matching placebo will be given once per day from the start of enteral feeds until the subject reaches 36 weeks corrected gestational age (GA) or is discharged from the hospital, whichever occurs first. Study Product will be administered via nasogastric or orogastric tube. For subjects who are no longer tube fed, the study product will be administered orally. Study product will be withheld when infant is NPO. Study product doses will be restarted when PO is resumed. 53  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT

[0213] Data will be collected at key timepoints as well as ongoing throughout the study. Lactation support will be provided to Caregivers as needed throughout the study. Key data timepoints include birth, Day 0, Day 7, Day 14, Day 21, and continuing weekly until study completion. Subject stool samples and anthropometrics measures will be obtained weekly during the Treatment Period.

[0214] Blood samples will be collected at the following timepoints: weekly, or more frequently depending on degree of inter-current illness and timed clinical blood draws. Data collected during the screening period will include, but is not limited to, gestational age, birth weight, mode of birth, use of perinatal antibiotics, steroid use during pregnancy, Apgar scores, perinatal birth events especially any signs of fetal newborn distress or birth asphyxia, newborn empiric antibiotics within first 72 hours of birth and type of feeding. Key data points collected throughout the study in an ongoing manner include (but are not limited to) details of NEC, hematochezia, and anemia; feeding intolerance (cumulative days of NPO, time to full feeds); type of feeding; adverse events including clinical sepsis and Spontaneous Intestinal Perforation (SIP); stooling pattern- consistency and frequency; and concomitant medications, including any antibiotics. The Electronic Medical Record (EMR) will be used to document these key data points as well as details of infant feeding and study product usage.

[0215] The primary efficacy analysis will be based on the Intention-to-Treat (ITT) analysis set, which will include all randomized infants. A Per-Protocol (PP) analysis will be conducted including all subjects who were randomized to receive Study Product and who completed the Treatment Period in general accordance with the protocol. The methodology such as the reasons for exclusion of subject data will be defined in the Statistical Analysis Plan (SAP) and documented in the final study report. Any sensitivity analyses or other analyses will be defined in the SAP.

[0216] The Safety Analysis Set will include all randomized infants who receive at least one single-serving dose of Study Product. If infants receive a treatment other than that to which they are randomly assigned to receive, safety data will be analyzed according to the predominant Study Product received. The proportion of infants with AEs will be determined during the Treatment Period and throughout the entire study. Treatment comparisons with respect to the cumulative incidence of NEC, hematochezia, and anemia will be based on the Kaplan-Meier method with standard errors approximated by the Greenwood formula. Incidence of hematochezia between the two treatment groups will be assessed by nominal logistic regression with the presence or absence of hematochezia as the nominal dependent variable, and treatment group (B. infantis EVC001 or placebo) as an independent variable. Other independent variables will include those that are unbalanced between the treatment groups at randomization, and factors that could affect the risk of hematochezia (these would include gestational age and birth weight, mode of delivery, type of feeding, time to initiation of the study product, gender, infections, antibiotic administration, etc.). Adjusted odds ratios will be generated from the final model. The effect of treatment assignment on NEC severity (score 0, 1, 2 or 3) will be assessed by Chi-square analysis. Time to clinical manifestation of NEC in the two different groups will be assessed by Kaplan-Meier analysis. Other secondary endpoints and the exploratory 54  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT endpoints will be summarized using descriptive statistics. Any additional formal statistical evaluations or analyses will be described in the SAP. One database lock (DBL) is planned for this study. The DBL will occur after 100% of the subjects have completed the study or have been discontinued from the study prior to study completion. Further details will be provided in the SAP (note: separate SAPs can be prepared for the interim and final analyses). EXAMPLE 2. Preparation of medicaments

[0217] For illustrative purposes, a powder medicament can be prepared using the following steps: 1) B. longum subsp infantis EVC001 (is obtained from the American Type Culture Collection (ATCC) (Washington DC, USA); 2) a seed culture of this organism is added to a sterile De Man, Rogosa and Sharpe agar (MRS) growth medium comprising 2% lactose and bovine milk oligosaccharides (BMO) at a concentration of 10 g / L to produce an activated form according to according to PCT / US2015 / 057226;3) the culture is then incubated for 24-48 hr. at 37C, under strictly anaerobic conditions, harvested by centrifugation, mixed with a cryopreservative selected from one or more of maltodextrin, trehalose, lactose, LNT, LnNT, inulin, pea protein and freeze dried; and 4) the freeze dried concentrated medicament is milled to a powder, packaged under nitrogen and stored at - 20 C until ready for blending. The dry cell concentrate has a bacterial mass with a count of 300 B CFU / g. The cell concentrate is then blended with lactose for a minimum bacterial count of 8 billion CFU / dose, 1 billion CFU / dose, 100 million CFU / g.

[0218] A liquid medicament can be prepared using the following steps: 1) B. longum subsp infantis EVC001 is obtained from the American Type Culture Collection (ATCC) (Washington DC, USA); 2) a seed culture of this organism is added to a sterile Bifidobacterium Broth (HiMedia M1395) growth medium comprising 2% dextrose and the mammalian milk oligosaccharide lacto-N- neotetraose (LNnT) at a concentration of 5 g / L; 3) the culture is then incubated for 24-48 hr. at 37C, under strictly anaerobic conditions, harvested by centrifugation, mixed with a cryopreservative of inulin plus maltodextrin and freeze dried; and 4) the freeze dried medicament is milled to a powder, packaged under nitrogen and stored at -20 C with a count of at least 10 B CFU / g. The dry cell concentrate is then milled a second time and blended with medium chain triglycerides (MCT) oil, residual bacterial fermentation supernatant, and LNT for a bacterial count of at least 100 M CFU / g.

[0219] A liquid medicament can be prepared using the following steps: 1) B. longum BB536 is obtained from the American Type Culture Collection (ATCC) (Washington DC, USA); 2) a seed culture of this organism is added to a sterile Brain Heart Infusion (BHI) growth medium comprising 2% dextrose and BMO at a concentration of 20 g / L; 3) the culture is then incubated for 24-48 hr. at 37C, under strictly anaerobic conditions, and harvested by diafiltration to concentrate cells, and 4) the cell concentrate is resuspended in a lyoprotectant of sucrose, LNnT, and MCT oil, and dispensed into vials which are frozen and stored at -20 C with a bacterial count of at least 1 B CFU / g. 55  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT

[0220] Lacto-N-tetraose (LNT), algal DHA oil at 40% DHA content, and Vitamin D are purchased in bulk from a commercial manufacturer such as DSM (Harleen, Netherlands or Parsippany, NJ USA). Various medicaments are made up according to the compositions in Table 3.

[0221] In cases where trials include a control placebo arm, placebo will consist of ingredients in final formulation that are not bioactive / microbial.

[0222] Table 3 shows exemplary medicaments comprising activated B. infantis EVC001 as the LBT and additional components including HMO, DHA, and Vitamin D.

[0223] Table 3. Medicament Constituents Med #1 Med #2 Med #3 Med #4 Med #5 Med #6 Bifidobacterium 10 B cfu 1 B cfu 1 B cfu 1 B cfu 100 M cfu 10 M cfuEXAMPLE 3. Infant gut remodeling as measure of medicament potency in clinical trials

[0224] A breast-fed term infant with detectable blood in the stool, as measured by one of the three assays described above (Example 1A), is deemed to have FPIAP and is ready for treatment with a medicament as described herein, e.g., Medicament #1 (see e.g., Table 2). Additional measures of gut dysbiosis and possible FPIAP are as follows. Stool samples or swabs will be processed for DNA extraction and subsequent analysis (e.g., targeted qPCR, 16s sequencing, or shotgun metagenomics for taxonomic or functional profiling). In term infants, before treatment, microbiome analysis of the baseline stool swab indicates that B. infantis represents less than 5% of the total gut microbiome and the total Enterobacteriaceae represents over 20% of the gut microbiome. Levels of antibiotic resistance genes are relatively high (e.g., greater than 0.5% relative abundance compared to the overall metagenome) as measured using the method described in Casaburi et al., Antimicrobial Resistance and Infection Control (2019) 8:131. Biomarkers of poorly functioning microbial metabolic activity will be present at baseline sampling. For example, elevated levels of HMO are detected in the stool (e.g., greater than 30 mg / g feces), as measured by the methods described by 56  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT Bajorek et al., Frontiers in Pediatrics (2022) 9:795970, and elevated levels of mucin derived o-linked glycans are detected in the stool (e.g., greater than 20% of the fecal glycan pool), a sign of mucus layer degradation, as measured by the methods described in Karav et al. FEBS Open Bio 8 (2018) 1649–1657.

[0225] In term infants, stool samples taken 1 week or 1 month after initiating the daily consumption of Medicament #1, can indicate that the B. infantis levels have risen to over 30% of the gut microbiome, or greater than 1E8 CFU / mg DNA from stool, and the Enterobacteriaceae have dropped to less than 20% of the gut microbiome. This indicates that a significant microbiome remodeling of the FPIAP patient’s gut microbiome can be affected by the treatment with Medicament #1. Similar LBT-containing medicaments can be expected to effect similar microbiome remodeling in patients diagnosed with or at risk for FPIAP.

[0226] In preterm infants, baseline stool samples indicate that B. infantis represents less than 5% of the total gut microbiome and Enterobacteriaceae represent greater than 45% of the gut microbiome. Stool samples taken 1 week after initiating the daily consumption of Medicament #1, can indicate that B. infantis levels have increased to greater than 30% of the gut microbiome and Enterobacteriaceae have reduced to less than 30% of the total gut microbiome. Similar medicaments are expected to have a similar effect on the microbiome for preterm infants diagnosed with or at risk for hematochezia. EXAMPLE 4. Resolution or prevention of FPIAP and resolution of hematochezia

[0227] Example 4 A: When comparing control to treatment arms, subjects treated with the medicament will indicate a faster resolution rate of FPIAP, as measured by the number of days to the absence of occult blood in stool. By the end of the study, the following observations can be noted in the treatment arm subject’s stool in comparison to the pretreatment samples: 1) stool occult blood is no longer detectable; 2) the stooling pattern is reduced from 4-6 watery stools per day to 2 well-formed stools per day; 3) the B. infantis levels remain over 30% of the total gut microbiome and Enterobacteriaceae remain under 20%; 4) a greater than 50% reduction of HMO detected in stool; 5) a greater than 70% reduction of mucin glycans detected in the stool (evidence of mucus layer erosion); 6) a greater than 70% reduction of antibiotic gene carriage and; 7) proinflammatory cytokine levels in the stool have been reduced by over 50% indicating a resolution of the chronic enteric inflammation caused by FPIAP.

[0228] Example 4 B: At the 12 mos of age time point, the treatment study arm will indicate a lower incidence of FPIAP in contrast to the control arm. Depending on the recruitment region, baseline FPIAP incidence is expected to range from 1%-20% (e.g., 4%-17%) within the control arm. 57  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT

[0229] Example 4 C: A comparison of control to treatment arms will indicate a and higher likelihood and faster resolution of hematochezia, as measured by gross blood in stool and days to resolution. At the end of the study, the following observations can be noted in the preterm subject’s stool in comparison to pretreatment samples: 1) stool occult blood is no longer detectable; 2) the B. infantis remains at over 30% of the total gut microbiome and Enterobacteriaceae at 30% of the gut microbiome; 3) greater than 70% reduction of HMO detected in stool; 4) a greater than 50% reduction of antibiotic gene carriage; 5) proinflammatory cytokine levels in the stool have been reduced by over 50% indicating a resolution of the chronic enteric inflammation caused by hematochezia; and 6) less feeds withheld from subjects. EXAMPLE 5. Evaluation of metagenomic profiles of infants who later go on to develop allergic disease and those that do not

[0230] While mechanism remains unclear, infants who develop FPIAP and / or FPIES are at an increased risk for developing other allergic or autoimmune diseases, such as IgE-mediated food allergy (Cetinkaya, P. G., Ocak, M., Sahiner, U. M., Sekerel, B. E. & Soyer, O. Food protein–induced allergic proctocolitis can have distinct phenotypes. Ann Allergy Asthma Immunol 126, 75–82 (2021)). FPIAP resolves for most infants within 12 mos of life; thus, FPIAP can serve as an early biomarker for allergic and autoimmune disease development. High abundance of Bifidobacterium is associated with decreased enteric and systemic inflammation and ordered immune development (see e.g., Rhoads et al., Journal of Pediatrics 203: 55-61 (2018); Henrick et al., Pediatric Research 86(6): 749-757 (2019); Henrick et al., Cell 184(15): 3884-3898 (2021); the contents of each of which are incorporated herein by reference in their entireties). Specifically, increased abundance of Bifidobacterium by feeding Bifidobacterium longum subps. infantis EVC001 to infants receiving human milk significantly dampened chronic, low-grade inflammation in both preterm and term infants (see e.g., Henrick et al, 2019, supra; Nguyen et al, Front Pediatr.16(9): 618009 (2021)) and generated a milieu that polarized naïve CD4+ T cells towards Th1 instead of Th2 and Th17 CD4+ T cells (Henrick et al, 2021, supra). The improved inflammatory profiles were strongly associated with higher abundance of human milk oligosaccharide (HMO) utilization genes (HUGs) encoded by B. infantis (see e.g., Nguyen et al, 2021, supra; Henrick et al, 2021, supra). Acquisition of these HUGs provided the genetic capability to produce glucosidases, transport proteins, and urease-related proteins to increase utilization of HMOs and convert these otherwise indigestible glycans into usable fuels and produce key bacterial metabolites that used in immune imprinting. These data provide a ‘key’ to unlock the reason why some children develop autoimmune and allergic diseases (aka non-communicable diseases (NCDs)).

[0231] Using a publicly available data set (see e.g., Vatanen et al, Cell, 165(4): 842-853 (2016), the content of which is incorporated herein by reference), which has functional metagenomics (of the 58  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT microbiome), meta-data for allergic and autoimmune antibodies later in life, HUGs CPM abundance, KEGG, and overall functional groupings, data analysis evaluated whether a correlation exists between HUGs in the metagenome and autoimmune and allergic disease development later in life. This evaluation identified a correlation between the gut microbiome genomics of ‘Carbohydrate Transport’, ‘HMO Carbohydrate Metabolism’, and ‘Urea Related’ functional groups and IgE egg, peanut, milk, and auto antibody positivity rates, respectively.

[0232] Data Analysis Methods. A sample collected at 6 months or next closest sample not exceeding the 6 month timepoint was selected to be evaluated for each subject. Subjects were separated into groups based on allergy development status, autoantibody levels, or Total IgE levels. HUGS CPM values and KEGG CPM values were compared across groups using Wilcoxon-Mann- Whitney test with FDR-correction. FDR-corrected P-values were considered statistically significant if < 0.05. Table 4 shows the distribution of subjects based on allergy development status, autoantibody levels, or Total IgE levels.

[0233] Table 4. Allergy Status of Subjects Analyzed Allergy Developed (n) No Allergy (n) Egg Allergy 20 68 58 88Seroconverted 1 89High IgE 24 64 HUs Va ues (groupe y unct on) an Vaues were compare across groups (i.e., Allergy Developed vs. No Allergy) for each allergy type (i.e., egg, milk, peanut, autoimmune seroconversion, and total IgE). Results for Milk Allergy are shown in Figure 1 as an example. In all allergy types, CPM values for ‘Carbohydrate Transport’ HUGs were significantly lower in subjects who developed the allergy type. In egg and milk allergies, CPM values for ‘HMO Carbohydrate Metabolism’ HUGs were also significantly lower in the subject’s metagenomes. In autoimmune seroconversion, CPM values for ‘Urea Related’ HUGs were also significantly lower. These data suggest total abundance of HUGs, and carbohydrate transport and HMO metabolism genes, in particular, determines risk of developing autoimmune and allergic disease in newborn children.

[0234] The relative abundance of the HUGs in the metagenomics was analyzed with the relative abundance of Enterobacteriaceae to determine if specific HUGs are associated with the dramatic decrease in Enterobacteriaceae. The correlations are presented in Table 5. 59  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT

[0235] Table 5: Correlated HMO genes with Enterobacteriaceae abundance var1 var2 cor p p.adj Enterobacteriaceae Blon_0104 0.02 0.853 0.85656478 Enterobacteriaceae Blon_0105 0.044 0.688 0.69502462 Enterobacteriaceae Blon_01060.589 0.59680602 Enterobacteriaceae Blon_0107 -0.027 0.807 0.81231239 Enterobacteriaceae Blon_0108 0.067 0.539 0.54779335 Enterobacteriaceae Blon_0109 0.054 0.621 0.62847292 Enterobacteriaceae Blon_0110 0.1 0.336 0.34735833 Enterobacteriaceae Blon_0111 0.1 0.352 0.36322945 Enterobacteriaceae Blon_0112 0.13 0.216 0.22936364 Enterobacteriaceae Blon_0113 0.1 0.356 0.36713182 Enterobacteriaceae Blon_0114 0.06 0.583 0.59143908 Enterobacteriaceae Blon_0115 0.086 0.43 0.44155067 Enterobacteriaceae -0.22 0.0438 0.04984547 Enterobacteriaceae Blon_0244 -0.19 0.082 0.0917658 Enterobacteriaceae Blon_0245 -0.22 0.0405 0.04624644 Enterobacteriaceae Blon_0247 0.077 0.481 0.49152005 Enterobacteriaceae Blon_0248 0.057 0.603 0.61062372 Enterobacteriaceae Blon_0423 -0.16 0.152 0.16473196 Enterobacteriaceae Blon_0426 0.0093 0.932 0.93310952 Enterobacteriaceae -0.31 0.00331 0.00417348 Enterobacteriaceae Blon_0641 -0.15 0.162 0.17466923 Enterobacteriaceae Blon_0642 0.038 0.727 0.73354169 Enterobacteriaceae Blon_0643 0.18 0.1 0.11058514 Enterobacteriaceae Blon_0644 -0.006 0.95656871 Enterobacteriaceae Blon_0645 0.11 0.31479061 Enterobacteriaceae Blon_0646 -0.00230.984 Enterobacteriaceae Blon_0647 -0.077 0.484 0.49398544 Enterobacteriaceae Blon_0648 -0.011 0.919 0.92064205 Enterobacteriaceae Blon_0649 -0.16 0.131 0.14280104 Enterobacteriaceae Blon_0650 0.18 0.0911 0.10127574 Enterobacteriaceae Blon_0651 0.12 0.286 0.29860459 Enterobacteriaceae-0.28 0.00931 0.01116138 Enterobacteriaceae Blon_2172 -0.16 0.13 0.14180285 Enterobacteriaceae Blon_2173 -0.19 0.0857 0.09552512 Enterobacteriaceae Blon_2174 -0.26 0.014 0.01653652 Enterobacteriaceae Blon_2175 -0.37 0.000463 0.00068373 Enterobacteriaceae Blon_2176 -0.38 0.000325 0.00048983 Enterobacteriaceae Blon_2177 -0.36 0.000739 0.00104718 Enterobacteriaceae Blon_2331 -0.17 0.12 0.13157757 Enterobacteriaceae Blon_2332 -0.076 0.485 0.49440606 60  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT var1 var2 cor p p.adj Enterobacteriaceae Blon_2334 -0.16 0.13 0.14180285 7 7 6 9 9 6 7 6 7 2 4 9 2 6abundance of Enterobacteriaceae; this could not be generalized to all 58 HUGs. H5 cluster genes negatively correlated with Enterobacteriaceae abundance (i.e., H5 abundance correlated with decreased Entero, and vice versa), which shows that H5 cluster is associated with improved microbiome function and highlights how H5+ strains can be used in the compositions and methods described herein. Blon_0625 is not in an H-cluster, but Blon_0625 is annotated as a B-D-glucosidase which is useful in carbohydrate metabolism (mono / polysaccharide uptake and metabolism). EXAMPLE 6. Targeted metabolomics as a potential potency assay between treatment and control study arms

[0237] Potential potency assays for the medicament include, but are not limited to, targeted metabolomics of stool samples. A previous study is described as an example. All aspects of the study were approved by an Institutional Review Board, and all participants provided written informedconsent. Briefly, exclusively breastfed term infants were randomly selected to receive 1.8 × 1010colony- forming units (CFU) B. infantis EVC001 daily for 21 days (EVC001) starting at day 7 postnatal or to receive breast milk alone (control) and followed up to postnatal day 60 (see e.g., Frese, et al., (2017), Persistence of Supplemented Bifidobacterium longum subsp. infantis EVC001 in Breastfed Infants. Msphere 2, e00501-17; the content of which is incorporated herein by reference inits entirety). All mothers received lactation support throughout the study. The demographicinformation (e.g., age, sex, and gestational age) was collected from each participant. Here, stool samples from day 21 of the study were collected from infants who were fed EVC001 (n = 20) and 61  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT control infants (n = 20). The objective was to characterize the stool metabolic signatures between the two arms, specifically, because there were differential microbial communities between treatment and control.

[0238] Metabolomics Methods. To remove protein, dissociate small molecules bound to protein or trapped in the precipitated protein matrix, and to recover chemically diverse metabolites, proteins were precipitated with methanol using the GENOGRINDER 2000 (GLEN MILLS) followed by centrifugation. Extract was split into equal parts for analysis on the LC / MS / MS and Polar LC platforms. Software was used to match ions to an in-house library of standards for metabolite identification and for metabolite quantitation by peak area integration.

[0239] Fecal sample correlation of KEGG function and metabolites from the IMPRINT trial are shown in the Figure 2 color heatmap. KEGG vs. Metabolite Correlations CPM values of functional KEGG orthologs (KOs) associated with the utilization of HMOs were correlated with scaled metabolite profiles in an all-against-all Spearman correlation matrix for 40 subjects from the IMPRINT trial (EVC001 n = 20, Control n= 20). Additionally, correlation matrices were generated separately for the EVC001 cohort (n =20) and Control cohort. P-values were FDR-corrected, and correlations with adjusted p-values < 0.05 were considered statistically significant. Significant correlations were plotted on a heatmap with the shade representing the Spearman’s rho value.

[0240] Thirteen statistically significant metabolites in infants with High HUGs through B. infantis EVC001 feeding with human milk oligosaccharides are summarized in Table 6 and annotated for function in Table 7. Significant metabolites include, but are not limited to adenine, indolelactate, gulonate, lactate, N-acetylglucosaminylasparagine, sphingomyelin (d17:1 / 16:0, d18:1 / 15:0, d16:1 / 17:0), palmitic acid and hydroxystearic acid (PAHSA) (16:0 / OH-18:0), sedoheptulose, serotonin, indole, phenyllactate (PLA), 4-hydroxy-phenyllactate (4-OH-PLA), N-acetylneuraminate (Neu5Ac), nicotinamide riboside (NR), gamma-glutamylmethionine, glutamate, gamma-methyl ester.

[0241] Table 6. Top 13 metabolites produced by B. infantis EVC001 predominant microbiome. Fold Change biochemicalKEGG HMDB PUBCHEM62  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT gamma- glutamyl- HMDB29155 7009567 19.26 methionine  895-6357-5489.5Attorney Docket No: 096910-000100WOPT Phenyllactate (PLA)0.00031197 0.000299302 0.8329 3.4815

[0242] Table 7. Functional annotation of stool metabolites enriched in infants from the B. infantis EVC001 treatment arm. 64  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT Biochemical Gut / Key Function(s) Exemplary Reference(s) Name Brain adenine Gut one of four chemical bases in DNA White Pharmacology & 8) n : ar ) - ) :65  895-6357-5489.5Attorney Docket No: 096910-000100WOPT Biochemical Gut / Key Function(s) Exemplary Reference(s) Name Brain lactate Gut Microbiota-Derived Lactate Lee et al. Cell Host Microbe 24(6): : : : 5366  895-6357-5489.5Attorney Docket No: 096910-000100WOPT Biochemical Gut / Key Function(s) Exemplary Reference(s) Name Brain riboside or niagen are an alternativeEXAMPLE 7. Inflammatory profile for diagnosing FPIAP / FPIES or hematochezia and potency assay for treatment

[0243] FPIAP / FPIES and hematochezia result in an inflamed infant gut. Biomarkers for inflammation include chemoattractants, chemokines, cytokines, immune regulatory signals, proteins, and glycoproteins. Inflammatory biomarkers in the stool will be measured using a Meso Scale Discovery (MSD) microarray platform (MSD, Rockville MD USA) (see e.g., Fig.9A-9F) or multiplexed ELISA.

[0244] In particular, the following biomarkers will differ significantly between healthy infants and those diagnosed with FPIAP in addition to serving as a potency assay, including but not limited to: IL-1a, MIP1a, GM-CSF, TARC, MIP-1B, IL-16, IL-2, MCP-1, MCP-4, and VEGF. Relative to healthy controls, elevated fecal GM-CSF, TARC, MIP-1B, MCP-1, MCP-4, VEGF, and reduced IL- 1a can serve as a biomarker for FPIAP in infants. At least a 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold reduction in elevated fecal biomarkers relative to pretreatment or control arms samples can serve as a potency assay in clinical studies.

[0245] In the treatment arm, by effectively remodeling the gut microbiome post-medicament, specific biomarkers will differ significantly between treatment and control arms. The IFN-B biomarker is associated with elevated HUGs in the gut metagenome and is immune-modulatory in nature, promoting appropriate immune regulation. Alternatively, biomarkers for inflammation and reduced or absent HUGs in the gut metagenome consist of IL-4, IL-5, IL-1b, IL-13, MIP-3a, IL-17A, IL-31, IL-21, and IL-33. Resolution of FPIAP can be measured by At least a 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold reduction in biomarkers IL-4, IL-5, IL-1b, IL-13, MIP-3a, IL-17A, IL-31, IL-21, and IL-33 and an increase in IFN-B relative to pretreatment samples or control arm subject samples.

[0246] In an infant trial where subjects were supplemented with either EVC001 or breast milk alone (control) (Example 6), fecal cytokine concentrations and individual HUG abundance (CPM) were inversely related (for infant trial see, Frese, et al., (2017), Persistence of Supplemented Bifidobacterium longum subsp. infantis EVC001 in Breastfed Infants. Msphere 2, e00501-17). These data (Fig.3A-3F; methods below) highlight how the functional capacity of the gut microbiome impacts host enteric inflammatory profile, providing evidence for specific biomarkers to be impacted by gut microbiome remodeling via supplementation of a medicament to an infant. 67  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT

[0247] Bacterial DNA Methods. DNA was extracted from 296 stool swab samples stored in DNA / RNA shield lysis tubes (ZYMO RESEARCH, Irvine CA) using the ZYMOBIOMICS 96 MAGBEAD DNA kit (ZYMO RESEARCH). Extracted DNA was quantified using QUANTIT dsDNA Assay kit, high sensitivity (THERMOFISHER SCIENTIFIC, Waltham, MA) according to the manufacturer’s protocol. Libraries were prepared for each sample using the ILLUMINA NEXTERA DNA FLEX library kit (ILLUMINA, San Diego, CA) with unique dual indexes according to manufacturer guidelines. Libraries were pooled and submitted to a DNA Technologies core for sequencing on the Illumina NOVASEQ S4 flow cell. (ILLUMINA, San Diego, CA). Each lane of the S4 flow cell contained 96 libraries.

[0248] Metagenomics. Quality filtering and removal of human sequences. Demultiplexed fastq sequences were quality filtered, including adaptor trimming using Trimmomatic v0.36 with default parameters (see e.g., Bolger et al. (2014). Bioinformatics 30, 2114–2120; the content of which is incorporated herein by reference in its entirety). Quality-filtered sequences were screened to remove human sequences using GenCoF v1.0 (see e.g., Czajkowski et al. (2018). Bioinformatics 35, 2318–2319; the content of which is incorporated herein by reference in its entirety) against a non-redundant version of the Genome Reference Consortium Human Build 38, patch release 7 (GRCh38_p7; available on the world wide web at ncbi.nlm.nih.gov). Human sequence-filtered raw reads were deposited in the Sequence Read Archive (SRA; available on the world wide web at ncbi.nlm.nih. gov / sra) under the reference number, PRJNA390646.

[0249] FPIAP is also known as Eosinophil Proctocolitis because it is characterized by an ingress of eosinophils into the gut. In infants, one way to detect FPIAP in stool includes, but is not limited to detection of eosinophils. In particular, eotaxin can be used as a biomarker for FPIAP.

[0250] Eotaxin is expressed predominantly in eosinophils. The specificity of eotaxin for eosinophils is the consequence of the exclusive signaling of eotaxin-1, eotaxin-2, and eotaxin-3 through its receptor, CCR3. Described herein is the discovery that differences in cytokines can be detected in fecal samples (see e.g., Henrick, 2019, supra). Eotaxin can be measured (e.g., using ELISA or Meso Scale Discovery (MSD) microarray platform) in fecal samples and the levels correlated with severity of symptoms associated with FPIAP in infants. A threshold for eotaxin can be established and used to develop a point of care test to detect FPIAP and treatment options. As a non-limiting example, an elevated level of eotaxin can be at least 10% higher, at least 20% higher, at least 30% higher, at least 40% higher, at least 50% higher, at least 60% higher, at least 70% higher, at least 80% higher, at least 90% higher, at least 1 fold higher, at least 2-fold higher, at least 3-fold higher, at least 4-fold higher, at least 5-fold higher or more relative to eotaxin levels in a healthy control. EXAMPLE 8. B. infantis metabolites exposed to an in vitro premature enterocyte growth model 68  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT

[0251] In this study, fecal metabolite profiles of exclusively breastfed infants with B. infantis- dominated gut microbiomes were compared to those of control infants. Metabolite profiles were evaluated in an in vitro premature enterocyte growth model to explore mechanistically how EVC001 supplementation could reduce intestinal injury. To test differences in the fecal metabolomes, fecal waters (FWs) were prepared from stool samples sourced from the study referenced in Example 6 (Frese, et al., (2017), Persistence of Supplemented Bifidobacterium longum subsp. infantis EVC001 in Breastfed Infants. Msphere 2, e00501-17). Enterocyte proliferation was quantified with cellular respiration and ATP production assays, and cytotoxicity was quantified with a lactate dehydrogenase assay and cell viability.

[0252] Cellular ATP Methods. Human intestinal epithelial stem cells (hIESCs) derived from the small intestine and colon of preterm neonate donors were cultured and treated with 5% of EVC001- and Control- FW for 6 hours, followed by the ATP assay. The CellTiter-Glo® 2.0 Assay kit (Promega, Madison WI) was used to determine ATP concentrations according to the supplier's instructions. Plates were read for relative light units (RLU) using SpectraMax® i3x multi-mode microplate reader (Molecular Devices, San Jose CA).

[0253] Cell Viability Methods. hIESC 2D or 3D enteroid cultures were treated with EVC001- or Control- FW for 72 hours, respectively. Proliferation assays were performed with Cell Counting Kit-8 (CCK8, Sigma St. Louis MO) according to the manufacturer's protocol, and 460nm OD read by SpectraMax® i3x multi-mode microplate reader (Molecular Devices, San Jose CA).

[0254] LDH Cytotoxicity Methods. Caco-2 or HIEC-6 cells were grown in media alone, 5% EVC001 or 5% Control FW. The CytoTox-ONETM(Promega, Madison WI) assay measured extracellular levels of lactate dehydrogenase according to supplier protocols. Fluorescence was recorded with an excitation wavelength of 560nm and emission wavelength of 590nm by SynergyTMHT multi-detection microplate reader (BioTek, Winooski VT).

[0255] Formate Toxicity Methods. hIESCs were grown to confluency and media supplemented with either PBS, Control FW, or EVC001 FW for 24 hours. Cells were challenged with 50 mM formate or PBS. Cell viability assay was performed after 48 hours as described above.

[0256] Extracellular Flux Methods. Oxygen consumption rate (OCR) was measured with an XFe24 Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica MA) according to manufacturer’s instructions. DMEM cell culturing medium was replaced with medium containing EVC001 or Control FW for 6h, following which the growth medium was replaced with DMEM and incubated before starting the mitostress assay. Parameters such as ATP-linked OCR, maximal OCR, reserve capacity, and proton leak were calculated from Mito Stress assays of three independent experiments as previously described.

[0257] Transepithelial Electrical Resistance Methods. Caco-2 cells were seeded onto transwell permeable supports (Corning, Corning NY). Transepithelial electrical resistance (TEER) was then evaluated using an EVOM volt-ohm meter (World Precision, Sarasota FL) in triplicate per 69  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT well to measure cell growth over time. Daily TEER measurements of Caco-2 cells were taken for 8 days.

[0258] Figure 4A-4F represents enterocyte proliferation in both proliferating and differentiated intestinal epithelial cells (IECs) exposed to EVC001 or Control fecal water.

[0259] ATP is critical for many cellular processes and can be used to gain insights to cellular metabolic activity. Therefore, we quantified ATP production (Fig.4A). ATP production in EVC001 FW-exposed proliferating HIEC-6 was significantly increased compared to medium-exposed IECs (Fig 4A; P = 0.0005). Using primary cells in a proliferating state, we evaluated the role of bacterial metabolites on viable growth and observed a significant increase in total cell number (OD) in primary enterocytes exposed to EVC001 compared to Control FW (Fig 4B; P = 0.05). In proliferating primary premature enterocytes, ATP production was significantly increased after exposure to EVC001 FW in small intestinal cells compared to control FW (Fig 4C; P = 0.021) and in colonic cells compared to control FW and medium alone (Fig 4D; P = 0.0001, P = 0.011, respectively). Similarly, differentiated small intestinal and colonic cells showed significantly increased ATP production when incubated with EVC001 compared to control FW (Fig 4E-4F; P = 0.024, P = 0.029, respectively). Taken together, these data indicate that gut microbiome composition and subsequent bacterial metabolite profiles can play an essential role in enterocyte development. Here, physiological levels of B. infantis EVC001 metabolites improved growth in both small intestinal and colonic IECs.

[0260] Figure 5A-5C represents how mitochondrial respiration and capacity were increased when hIESCs were treated with EVC001 FW instead of Control. To further elucidate a mechanism of action by which bacterial metabolites from B. infantis EVC001 FW improved enterocyte proliferation, mitochondrial extracellular flux assays were used to observe mitochondrial activity and ATP production in primary IECs (Peternel, et al., (2000) Comparison of 3 Cytotoxicity Screening Assays and Their Application to the Selection of Novel Antibacterial Hits. Slas Discov; 14:142–50.). A significant decrease was observed in basal respiration in cells treated with control FW compared to cells treated with EVC001 FW or PBS alone (Fig 5A; P = 0.0023, P = 0.0045, respectively). Conversely, EVC001 FW significantly increased ATP-specific respiration compared to control FW or PBS alone (Fig 5B; P = 0.018, P = 0.044, respectively). Overall mitochondrial maximal respiratory capacity (MRC) was significantly increased in hIESCs after exposure to EVC001 FW compared to control FW exposure (Fig 5C; P = 0.015). These data indicate that increased ATP from EVC001 FW- exposed IECs is associated with increased cellular respiration and improved capacity to accommodate increased energy requirements.

[0261] Figure 6A-6C represents the cytotoxic and protective effects of EVC001 FW on adult and premature enterocyte cell lines in contrast to Control FW. LDH is released extracellularly when the integrity of the cell membrane is compromised; therefore, it is used as a marker of cellular cytotoxicity (Kumar, et al., (2018) Analysis of Cell Viability by the Lactate Dehydrogenase Assay. Cold Spring Harb Protoc. pdb.prot095497). After 24 hours, Caco-2 incubated with EVC001 FW 70  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT showed significantly decreased LDH compared to IECs incubated with control FW (Fig 6A; P = 0.05). HIEC-6 exposed to either EVC001 or control FW had significantly decreased levels of LDH release compared to the medium alone (Fig 6B; P = 0.003, P = 0.01, respectively).

[0262] Given that we have previously identified that increased formate correlates with NEC diagnosis in premature infants,we next determined whether EVC001 or control FW had a protective effect against formate toxicity in enterocytes. Primary IECs were exposed to formate at a level that causes cell cytotoxicity and cell growth (OD) was significantly decreased in hIESCs exposed to formate compared to medium alone (Fig.6C; P = 0.0026) (Hughes, et al., (2017). Microbial Respiration and Formate Oxidation as Metabolic Signatures of Inflammation-Associated Dysbiosis. Cell Host Microbe.21:208–219). When hIESCs were incubated with Control or EVC001 FW, there were protective benefits against cytotoxicity, especially in the EVC001 FW exposed cells compared to medium alone and Control FW treated cells (Fig.6C; P = 0.0022, P = 0.0043, respectively). Control FW showed protective effects compared to medium alone to a lesser extent. (Fig.6C; P = 0.015). These data suggest that B. infantis EVC001 bacterial metabolites significantly decrease cell cytotoxicity compared to a microbiome devoid of B. infantis.

[0263] Figure 7A-7B shows specific bacterial metabolites at physiological levels from B. infantis EVC001-fed infants promotes gastrointestinal barrier function. IECs rely on bacterially produced organic acids as a significant source of energy used in cell homeostasis and proliferation, we therefore investigated if specific abundantly produced metabolites by B. infantis EVC001 would support the epithelial barrier function of enterocytes. Here, physiological concentrations of acetate, lactate, butyrate, or formate from control fecal samples did not significantly improve tight junction formation or epithelial integrity as shown by TEER measurements compared to unseeded wells with PBS medium (Fig.7A). Conversely, levels of acetate, lactate, and butyrate associated with EVC001 colonization significantly increased TEER compared to unseeded wells at day four and day eight post seeding (Fig.7.; acetate: P = 0.007, P = 0.005; lactate: P = 0.018, P = 0.002; butyrate: P = 0.006, P = 0.003, respectively). Formate did not affect epithelial integrity compared to control. These data provide quantifiable measures of improvement to the barrier function of IEC in response to physiological concentrations of specific bacterial metabolites found in EVC001-fed infants compared to infants not colonized with B. infantis.

[0264] When chronic enteric inflammation is present in the newborn, energy demands are exacerbated and the possibility of barrier failure and bloody stool can increase; similar to the clinical outcomes measured when diagnosing FPIAP or hematochezia. Therefore, the availability of ATP and increased mitochondrial respiration capacity in the context of high B infantis, or HUGs, levels can contribute to both cellular survival and epithelial integrity. Thus, a medicament containing B. infantis or a Bifidobacterium could provide immediate and long-term clinical benefit to the newborn gut, either preventatively or as an intervention. 71  4  895-6357-5489.5

Claims

Attorney Docket No: 096910-000100WOPT CLAIMS What is claimed herein is:

1. A method of treating, preventing, or reducing the severity of symptoms of bloody stool in an infant patient in need thereof, the method comprising administering an effective amount of a medicament comprising one or more Bifidobacterium species.

2. The method of claim 1, wherein the Bifidobacterium species is selected from the group consisting of: Bifidobacterium breve, Bifidobacterium longum subsp longum, Bifidobacterium longum subsp infantis, Bifidobacterium longum subsp suis, Bifidobacterium pseudolongum, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Bifidobacterium catenulatum, Bifidobacterium bifidum, and Bifidobacterium dentium.

3. The method of claim 2, wherein the Bifidobacterium species is B. longum subspecies infantis.

4. The method of claim 3, wherein the Bifidobacterium comprises a functional H5 gene cluster that transports and metabolizes lacto-N-biose HMO derivates present in human milk.

5. The method of claim 4, where the functional H5 gene cluster comprises genes comprising greater than 90% sequence identity to the nucleic acid sequences of Blon_2171, Blon_2172, Blon_2173, Blon_2174, Blon_2175, Blon_2176, and / or Blon_2177.

6. The method of claim 5, wherein the functional H5 gene cluster is capable of expressing Blon_2171, Blon_2172, Blon_2173, Blon_2174, Blon_2175, Blon_2176, and Blon_2177.

7. The method of claim 6, wherein function of the Bifidobacterium is assessed by expression and activity of Blon_2176 in a reconstituted dried Bifidobacterium species or strain to transport and metabolize lacto-N-biose HMO derivatives present in human milk.

8. The method of claim 2, wherein the Bifidobacterium species expresses genes with at least 75% sequence identity to at least 9 of the genes selected from the group consisting of: Blon 2334-2336, BLON 0243-0248, and Blon 0423-0428.

9. The method of any one of claims 3-8, wherein the Bifidobacterium species is B. infantis strain EVC001 (ATCC Accession No. PTA-125180) or ATCC strain 15697.

10. The method of any one of claims 1-9, wherein the Bifidobacterium is activated.

11. The method of any one of claims 1-10, wherein the infant patient receives 101to 1013cfu of the Bifidobacterium per day.

12. The method of any one of claims 11, wherein, the infant patient receives at least 10 million – 100 million CFU of the Bifidobacterium per day.

13. The method of claim 11, wherein in the infant patient receives at least 100 million to at least 1 Billion CFU of the Bifidobacterium per day 72  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT 14. The method of claim 11, wherein the infant patient receives at least 1 billion to at least 8 billion CFU of the Bifidobacterium per day.

15. The method of any one of claims 11-14, wherein the Bifidobacterium is provided in a unit dose of 101to 1013cfu per dose.

16. The method of claim 15, wherein the unit dose is given 1-12 times per day to reach the total daily intake.

17. The method of any one of claims 1-16, wherein the Bifidobacterium is in combination with a cryoprotectant.

18. The method of claim 17, wherein the cryoprotectant is selected from the group consisting of: sucrose, trehalose, maltodextrin, inulin, pea protein, milk fat globule membrane, glycomacropeptide (GMP), LNT, and LNnT, and combinations thereof.

19. The method of claim 17 or 18 wherein the cryoprotectant and Bifidobacterium mixture are frozen as a liquid product or dried (freeze-dried or spray-dried).

20. The method of any one of claims 1-19, wherein the Bifidobacterium is in combination with an excipient selected from the group consisting of: lactose, MCT oil, MFGM, maltodextrin, LNT, LNnT, 2’FL, 3FL, infant formula, an exempt infant formula, human milk fortifier, and human milk product, and combinations thereof.

21. The method of any one of claims 1-20, further comprising a second component selected from an HMO, a vitamin, and / or a source of DHA or other bacterial species.

22. The method of claim 21, further comprising a third component selected from an HMO, a vitamin, and / or a source of DHA.

23. The method of claim 22, further comprising a fourth component selected from an HMO, a vitamin, and / or a source of DHA.

24. The method of any one of claims 21-23, wherein: (a) the HMO is selected from one of more of the group consisting of: lacto-N-biose (LNB), N-acetyl lactosamine, lacto-N-triose, lacto-N-tetraose (LNT), lacto-N- neotetraose (LNnT), fucosyllactose (FL), lacto-N-fucopentaose (LNFP), lactodifucotetraose, (LDFT) sialyllactose (SL), disialyllacto-N-tetraose (DSLNT), 2'- fucosyllactose (2FL), 3’-sialyllactosamine (3SLN), 3'-fucosyllactose (3FL), 3'-sialyl- 3-fucosyllactose(3S3FL), 3'-sialyllactose (3SL), 6'-sialyllactosamine (6SLN), 6'- sialyllactose (6SL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFPI), lacto- N-fucopentaose II (LNFPII), lacto-N-fucopentaose III (LNFPIII), lacto-N- fucopentaose V (LNFPV), and sialyllacto-N-tetraose (SLNT), and their derivatives, and combinations thereof; (b) the HMO is LNT at 0.5 -10g / d; (c) the vitamin is selected from the group consisting of: Vitamin A (retinol, carotenoids), Vitamin B (thiamine, riboflavin, niacin, niacinamide, pantothenic acid, pyridoxine, 73  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT pyradoxamin, pyridoxal, biotin, folic acid, folate, folic acid, cyanocobalamin, hydroxocobalamin, methylcarbylamine), Vitamin C (ascorbic acid), Vitamin D (cholecalciferol, ergocalciferol), Vitamin E (tocopherols, tocotrienols), and Vitamin K (phylloquinone, menaquinone); (d) the vitamin is Vitamin D at 5-25 ug / d; (e) the DHA source is selected from the group consisting of: fish oil, algal oil, and oil from recombinant plants or microorganisms; (f) the DHA is a triglyceride delivering 1-50 mg DHA / d; and / or (g) the other bacterial species are selected from Akkermansia and Lactobacillus, optionally wherein the Akkermansia species is selected from the group consisting of: Akkermansia muciniphila and Akkermansia glycaniphila; optionally wherein the Lactobacillus species is selected from the group consisting of: Lactobacillus crispatus, Lactobacillus johnsonii, Lacticaseibacillus rhamnosus, Limosilactobacillus reuteri, and Lacticaseibacillus paracasei.

25. The method of any one of claims 1-24, wherein: (a) the medicament is formulated as a powder; (b) the medicament is formulated as a gel, butter or paste; (c) the medicament is formulated as a liquid suspension; (d) the medicament is formulated as an oil; (e) the medicament is formulated as a foam; (f) the medicament is formulated to be delivered orally; and / or (g) the medicament is formulated to be delivered as a suppository.

26. The method of any one of claims 1-25, wherein the medicament comprises a food, a food for special dietary use (FSDU), a medical food, a dietary supplement, or a live bacterial therapeutic (LBT).

27. The method of claim 26, wherein the medicament is manufactured and packaged at a pharmaceutical grade for use as a live bacterial therapeutic.

28. The method of claim 26, wherein the FSDU, medical food and / or dietary supplement is in combination with a preterm infant formula, term infant formula, soy-based formula, follow-on formula, bovine based human milk fortifier, human based human milk fortifier, expressed human milk, expressed pasteurized donor milk, enriched human whey permeate (dried or liquid), or purified human milk oligosaccharides from natural or synthetic sources.

29. The method of claim 28, wherein the medicament is added to the FSDU, medical food and / or dietary supplement at time of manufacture or at the time of consumption.

30. The method of claim 26, wherein the unit size of the FSDU, medical food and / or dietary supplement is a single serving or dose. 74  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT 31. The method of any one of claims 1-26, wherein the medicament is formulated for consumption by the infant patient.

32. The method of any one of claims 26-31, wherein the medicament prevents, treats, reduces, or resolves hematochezia and / or anemia in the infant patient.

33. The method of any one of claims 26-31, wherein the medicament treats, reduces, or resolves symptoms of FPIAP and FPIES in the infant patient.

34. The method of any one of claims 26-31, wherein the medicament prevents FPIAP or FPIES in the infant patient.

35. The method of any one of claims 31-34, wherein the infant patient is a term infant.

36. The method of claim 32, wherein the infant patient is a preterm infant.

37. The method of claim 35, wherein the term infant’s age is 0-3 months, 0-6 months, 6-12 months, 21-24 months, or 0-24 months.

38. The method of claim 36, wherein the preterm infant is extremely low birth weight (ELBW), very low birth weight (VLBW), low birth weight (LBW) and / or less than 33 weeks gestational age at birth or less than 31 weeks.

39. The method of any one of claims 1-38, wherein the infant patient is selected from an infant with risk factors for bloody stool selected from the group consisting of: prematurity, family history of bloody stool or food allergy, past history of atopic dermatitis, gut dysbiosis, C- section, antibiotic use, and cow’s milk protein sensitivity.

40. The method of any one of claims 1-39, wherein the patient or patient population is selected based on onset of symptoms selected from the group consisting of: bloody stools, IgE antibodies, autoantibodies, excessive crying, low anthropometric scores, poor cognitive scores, high level of enteric or systemic inflammation (e.g., > 200ug / mg fecal calprotectin), feeding difficulty, wheezing, vomiting, and reflux (GERD).

41. A method of treating, preventing, or reducing the severity of FPIAP, the method comprising administering an effective amount of a medicament comprising one or more Bifidobacterium species to an infant subject in need thereof.

42. The method of claim 41, wherein the medicament is administered in a background of or in combination with cow’s milk protein.

43. The method of claim 42, wherein the Cow’s milk protein is from addition of bovine based infant formula, transfer through breast milk (e.g., increased dairy consumption by a breast-feeding mother), yogurt, or cheese to the infant diet.

44. A method of treating hematochezia in an infant subject, the method comprising administering an effective amount of a medicament comprising one or more Bifidobacterium species to an infant subject in need thereof.

45. The method of claim 44, wherein the hematochezia is associated with FPIAP pr FPIES.

46. The method of claim 44 or 45, wherein: 75  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT (a) the medicament is provided within 1 hour, 2 hours, or up to 5 days after the day of diagnosis; (b) the medicament is provided on a daily basis for at least 1-100 days and / or until hematochezia or bloody stool is resolved; and / or (c) the medicament is provided to the subject one or more times / day but not exceeding the total daily intake.

47. The method of any one of claims 41-46, wherein the treatment is initiated within the first year of life.

48. The method of any one of claims 41-47, wherein the treatment is provided to one or both of a mother-infant pair in conjunction with breast-feeding.

49. The method of claim 48, wherein breastfeeding duration is increased.

50. The method of claim 48 or 49, wherein the mother is in the 3rdor 4thtrimester, or wherein the mother is breast-feeding.

51. A method of treating FPIAP or FPIES comprising: (a) identifying an infant patient with FPIAP by any one of the following symptoms: (i) elevated stool inflammatory markers; (ii) elevated eotaxin levels; (iii) bloody stool; (iv) stool B. infantis comprising less than 5% of the infant gut microbiome; (v) stool Enterobacteriaceae exceeding 20% of the infant gut microbiome; (vi) excess stool mucus; and / or (vii) feeding difficulty, wheezing, vomiting and / or reflux (GERD); (b) providing the patient with an effective amount of a medicament comprising one or more Bifidobacterium species according to a daily dose; and (c) monitoring the symptoms of the patient until any or all of the symptoms are resolved.

52. A method of treating hematochezia comprising: identifying an infant patient with hematochezia using a stool occult test; providing the patient with an effective amount of a medicament comprising one or more Bifidobacterium species according to a daily total intake; and monitoring the patient until the hematochezia is resolved.

53. A method of reducing the risk of IgE-based food allergies and / or asthma by treating patients with FPIAP or FPIES with an effective amount of a medicament comprising one or more Bifidobacterium species.

54. The method of 53, wherein the food allergy is elevated IgE for egg, milk, or peanut.

55. The method of any one of claims 41-54, wherein treatment efficacy is measured by one or more of: decreased gut pH, a change in metagenomic sequencing, reduction or enrichment of at least one metabolite, and / or change in inflammatory profile. 76  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT 56. The method of claim 55, wherein the at least one metabolite is selected from the group consisting of: adenine, N-acetylgluco-saminyl-asparagine, sphingomyelin, PAHSA, gamma- glutamylmethionine, glutamate gamma-methyl ester, lactate, sedoheptulose, indolelactate, N- acetylneuraminate (Neu5Ac), gulonate, serotonin, OH-PLA, indole, phenyllactate (PLA), 4- hydroxy-phenyllactate (4-OH-PLA), and nicotinamide riboside.

57. The method of claim 55, wherein the change in metagenomic sequencing comprises: an enrichment of HMO metabolizing genes and / or aromatic lactic acid pathways, and / or a reduction of antibiotic resistance genes and / or formate biosynthesis pathways.

58. The method of claim 55, wherein the change in metagenomic sequencing comprises B. infantis comprising greater than 30% of the total gut microbiome and Enterobacteriaceae comprising less than 20% of the total gut microbiome.

59. The method of claim 55, wherein the inflammatory profile comprises levels of one or more inflammatory cytokines selected from the group consisting of: IL-1α, MIP1a, GM-CSF, TARC, MIP-1B, IL-16, IL-2, MCP-1, MCP-4, VEGF, IFN-β, IL-13, MIP-3a, IL-17A, IL-31, IL-21, IL- 33, and eotaxin.

60. The method of claim 59, wherein fecal IL-1α, IFN-β, and Galectin-1 are increased, and fecal GM-CSF, TARC, MIP-1B, MCP-1, MCP-4, VEGF, IL-13, MIP-3a, IL-17A, IL-31, IL-21, IL-33, and eotaxin are decreased in comparison to pretreatment samples and / or control subject samples.

61. A method of treating, preventing, or reducing the severity of FPIAP or FPIES in an infant in need thereof, the method comprising administering a composition comprising a therapeutically effective amount of a Bifidobacterium to the infant, whereby FPIAP or FPIES is treated, prevented, or severity reduced.

62. The method of claim 61, wherein the method further comprises the step of monitoring the patient until any or all of the symptoms of FPIAP or FPIES are resolved.

63. The method of claim 61, wherein the method further comprises a step, before the administering step, of receiving diagnostic results indicating that the subject has FPIAP or FPIES.

64. The method of claim 61, wherein the method further comprises a step, before the administering step, of performing a diagnostic test for FPIAP or FPIES.

65. The method of claim 64, wherein diagnosis is based on one or more markers selected from the group consisting of: elevated stool inflammatory markers, stool B. infantis comprising less than 5% of the infant gut microbiome, stool Enterobacteriaceae exceeding 20% of the infant gut microbiome, and excess stool mucus.

66. The method of claim 65, wherein one or more stool inflammatory markers are selected from the group consisting of: IL-1α, MIP1a, GM-CSF, TARC, MIP-1B, IL-16, IL-2, MCP-1, MCP-4, VEGF, IFN-β, IL-13, MIP-3a, IL-17A, IL-31, IL-21, IL-33, and eotaxin.

67. A method of treating, preventing, or reducing the severity of hematochezia, the method comprising administering to a subject diagnosed with hematochezia, a composition comprising a 77  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT Bifidobacterium in an amount effective to treat, prevent, or reduce the severity of hematochezia, whereby the hematochezia is treated, prevented, or the severity reduced.

68. The method of claim 67, wherein the method further comprises identifying a patient at risk for hematochezia, using risk factors selected from the group consisting of: prematurity, low gestational age, low birth weight, increased time on Total Parenteral Nutrition (TPN), increased time to full feeds, increased nil per os (NPO), elevated stool inflammatory markers, stool B. infantis comprising 5% of the total gut microbiome, and Enterobacteriaceae comprising greater than 45%.

69. The method of claim 67, wherein the hematochezia is determined to be effectively treated when there is a decrease in time to full feeds, decrease in nil per os (NPO), and decrease in time on TPN.

70. The method of claim 67, wherein the hematochezia is determined to be effectively treated when B. infantis comprises over 30% of the total gut microbiome and Enterobacteriaceae comprises less than 30%.

71. The method of any one of claims 67-70, further comprising a step, before the administering step, of receiving diagnostic results indicating that the subject has hematochezia.

72. The method of any one of claims 67-71, where in the method reduces the incidence of spontaneous intestinal perforation, late onset sepsis, anemia, and / or necrotizing colitis.

73. The method of any one of claims 67-72, further comprising a step, before the administering step, of performing a diagnostic test for hematochezia.

74. A method for reducing the risk of IgE-based food allergy or asthma in an infant with FPIAP or FPIES, the method comprising administering a composition comprising a therapeutically effective amount of a Bifidobacterium to the infant, whereby the infant’s risk of IgE-based food allergy is reduced relative to an infant with FPIAP or FPIES not administered the composition.

75. The method of claim 74, wherein the Bifidobacterium is in a medicament.

76. A method of treating, preventing, or reducing the severity of FPIAP or FPIES, the method comprising administering a composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis EVC001, which is effective when reconstituted in vivo.

77. The method of claim 76, wherein the B. infantis is reconstituted at the time of consumption or in vivo.

78. A method of treating, preventing, or reducing the severity of hematochezia, the method comprising administering a composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis, which is effective when reconstituted in vivo.

79. The method of claim 78, wherein the B. infantis is reconstituted at time of consumption or in vivo.

80. A method of reducing the risk of IgE-based food allergy or asthma in an infant with FPIAP or FPIES, the method comprising administering a composition comprising a therapeutically effective 78  4  895-6357-5489.5Attorney Docket No: 096910-000100WOPT amount of a dried Bifidobacterium longum subsp. infantis, which is effective when reconstituted in vivo.

81. The method of claim 80, wherein the dried B. infantis is reconstituted at time of consumption or in vivo.

82. A composition comprising one or more Bifidobacterium species for use in an infant patient exhibiting symptoms of bloody stool.

83. A composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis EVC001 for use in the treatment of FPIAP or FPIES, which is effective when reconstituted in vivo.

84. A composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis for use in treating hematochezia, which is effective when reconstituted in vivo.

85. A composition comprising a therapeutically effective amount of a dried Bifidobacterium longum subsp. infantis for use in reducing the risk of IgE-based food allergy or asthma in an infant with FPIAP or FPIES, which is effective when reconstituted in vivo. 79  4  895-6357-5489.5

Citation Information

Cited By

  • Method for screening bifidobacteria based on metabolic capacity of tryptophan and strain of bifidobacteria

    CN122405802A